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3Abstract 
Urinary albumin-creatinine ratio is a marker of diabetic nephropathy and microvascular damage. 
Metabolic-related traits are observationally associated with ACR but their causal role is 
uncertain.  Here, we confirmed ACR as a marker of microvascular damage and tested whether 
metabolic-related traits have causal relationships with ACR.
The association between ACR and microvascular function (responses to acetylcholine and 
sodium nitroprusside) were tested in the SUMMIT study. Two sample Mendelian randomization 
(MR) was used to infer the causal effects of eleven metabolic risk factors, including glycemic, 
lipid and adiposity traits on ACR. MR was performed in up to 440,000 UK Biobank and 54,451 
CKDGen participants.
ACR was robustly associated with microvascular function measures in SUMMIT. Using MR we 
inferred that higher triglyceride and LDL-cholesterol levels caused elevated ACR. A one 
standard deviation (SD) higher triglyceride and LDL-C level caused a 0.062 [95%CI: 0.040, 
0.083] and a 0.026 [95%CI: 0.008, 0.044] SD higher ACR respectively. There was evidence that 
higher body fat and visceral body fat distribution caused elevated ACR, whilst a metabolically 
“favourable adiposity” phenotype lowered ACR.  
ACR is a valid marker for microvascular function. MR suggested that 7 traits have causal effects 
on ACR, highlighting the role of adiposity related traits in causing lower microvascular function.
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4Introduction
The urinary albumin-creatinine ratio, a marker of diabetic nephropathy, is used as a proxy for 
damage to the systemic microcirculation (1) and predicts first myocardial infarction and mortality 
in those with diabetes, post stroke and the general population (2-4). There is evidence linking 
metabolic-related traits, including adiposity, dyslipidemia and insulin resistance with elevated 
ACR levels and microvascular damage (5; 6). It is well accepted that tight glucose control in 
patients with type 2 diabetes (T2D) reduces the risk of microvascular retinal complications (7; 8) 
and there is evidence that adiposity per se is associated with increased ACR. For example, 
population studies suggest that microalbuminuria is associated with central adiposity (9) and 
results from The Framingham Heart Study show that visceral but not subcutaneous fat is 
associated with increased albuminuria (10). Not all evidence linking metabolic-related traits 
come from randomized control trials and, in absence of these, the next best evidence of 
causality comes from genetic studies using a technique known as Mendelian randomization 
(MR, Figure 1).
In MR, genetic variants that are strongly associated with the risk factor of interest are used to 
test its causal effect on an outcome (11). The MR approach exploits the natural experiment of 
genetic variants being randomly assigned at conception, which means they are less likely to be 
associated with confounding factors and should not suffer from reverse causality (12). MR 
studies investigating the role of metabolic traits in increasing microvascular damage, including 
ACR, infer causal relationships for higher blood pressure (13) but not for lipids (14), but the 
latter study was small, limited in power and focused only on people with diabetes.
Here, we utilised data from 743 participants in the SUrrogate markers for Micro- and Macro-
vascular hard endpoints for Innovative diabetes Tools (15) study to first confirm that ACR is a 
suitable proxy for early systemic microvascular damage, by testing its association with two 
validated measures of microvascular function – skin microvascular response to iontophoresis of 
vasodilators acetylcholine (endothelial dependent)  and sodium nitroprusside (endothelial 
independent). Second, we tested the observational associations between ACR and 9 metabolic 
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5risk factors in 438,075 participants in the UK Biobank. Finally, we used MR to test the effects of 
11 metabolic risk factors on microvascular function using ACR as a proxy in the UK Biobank 
and summary results for 54,451 participants in the CKDgen GWAS results.
Methods
Populations studied
UK Biobank
The UK Biobank study recruited over 500,000 individuals aged between 37 and 73 years 
between 2006 and 2010. The study collected detailed information from all participants, via 
questionnaires, interviews and measurements (16). Here we used 438,075 individuals of White 
European ancestry (defined through principal component-based analyses (17) with ACR 
available.  We also defined a subset of 368,754 unrelated individuals of European ancestry. 
Related individuals were defined using a KING Kinship and an optimal list of unrelated 
individuals was generated to allow maximum numbers of individuals to be included. Ancestral 
principal components were then generated within these identified individuals for use in 
subsequent analyses.
SUMMIT
Data for observational association and functional measures of microvascular function were 
collected in 743 individuals from two centres (Exeter and Dundee) participating in the vascular 
imaging cohort of the SUMMIT study. SUMMIT is a multicentre study aiming at identifying 
markers that predict the risks of developing diabetes related chronic micro- and macro-vascular 
complications (15; 18).
Validation of ACR as a proxy for microvascular function
In SUMMIT, skin microvascular function in the forearm is measured using laser Doppler 
fluximetry. A laser Doppler imager (LDI, Moor Instruments MODEL LDI2) was used to measure 
perfusion before and after iontophoresis of endothelium dependent (acetylcholine , ACH) and 
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6endothelium independent (sodium nitroprusside) vasodilatory stimuli. The full protocol of the 
techniques used are detailed elsewhere (18).
ACR was measured in SUMMIT from random spot urine collection (Exeter Pathology Services, 
Royal Devon and Exeter NHS Foundation Trust, and Dundee Pathology Services, Ninewells 
NHS trust), in accordance with the UK national quality assessment scheme. Analysis of albumin 
concentration was performed using immunoturbidimetric method a detection limit of 3.0 mg/L 
(Cobas system, Roche), creatinine was measured using the Jaffe methods. In order to maintain 
a consistent approach with UK Biobank analysis, values below detection limit were set at 2.9 
mg/L prior to the calculation of the ratio. The ACR variable was inverse normalised prior to 
analysis.
The relationship between the gold standard microvascular functional measures and ACR was 
explored using linear regression models, with age and sex included as covariates. 
Exposure and outcome measures in UK Biobank
We selected 11 metabolic markers which have previously been associated with ACR and have 
strong genetic instruments available in the form of multiple variants (Supplementary table 2) 
identified in large genome wide association studies (GWAS). More information on how the 
outcome and exposures were defined in the UK Biobank are explained below.
OUTCOME: Albumin to creatinine ratio (ACR)
A continuous measure of ACR was derived using urinary measures of albumin and creatinine. If 
albumin was <6.7 mg/L (the detection level of the assay in UK Biobank, 
http://biobank.ctsu.ox.ac.uk/crystal/docs/urine_assay.pdf) then the albumin was set at 6.7 mg/L 
prior to the calculation of the ratio, an approach consistent with that of previous studies (13; 19). 
Albumin was measured using immuno-turbidimetric analysis method (Randox Bioscience, UK) 
while creatinine was measured using enzymatic analysis method (Beckman Coulter, UK). The 
ACR variable was inverse normalised prior to analysis.
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7EXPOSURES:
Nine of the eleven metabolic markers were measured in the UK Biobank. 
Lipids
Serum concentrations of LDL-Cholesterol (LDL-C, N=417,386) were obtained using an 
Enzymatic Selective Protection analysis method (Beckman Coulter AU5800, Beckman Coulter 
(UK), Ltd), HDL-Cholesterol (HDL-C, N=382,598) using a EnzymeImmuno-inhibition analysis 
method (Beckman Coulter AU5800, Beckman Coulter (UK), Ltd) and triglycerides (TG, 
N=417,825) using Enzymatic analysis method (Beckman Coulter AU5800, Beckman Coulter 
(UK), Ltd). More details on the acquisition of these biomarkers can be found here: 
http://biobank.ndph.ox.ac.uk/showcase/docs/serum_biochemistry.pdf 
Body composition 
We used three measures of body composition: body mass index (BMI), waist hip ratio (WHR) 
adjusted for BMI and, using genetics, a measure of higher body fat percentage but lower 
metabolic disease risk, termed favourable adiposity. BMI was calculated for all participants from 
measured weight and height ((kg)/height (m)2) and was available for 436,631 individuals with 
ACR and genetic data available. WHR was calculated from measured waist and hip 
circumference measures and adjusted for BMI, this was available in 436,530 individuals.  Body 
fat percentage was calculated from bioelectrical impedance data collected using Tanita 
BC418MA body composition analyser and was available in 430,546 individuals.
Blood pressure
Systolic blood pressure (SBP, N=437,121) and diastolic blood pressure (DBP, N=436,394) were 
measured. The blood pressure readings were obtained from averaging two readings obtained in 
a seated position 5 minutes apart using an automated blood pressure device (Omron 705 IT, 
Omron Healthcare Europe B.V. Hoofddorp, The Netherlands). In participants where only one 
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8valid blood pressure was available this was utilised. Blood pressure medication use was 
accounted for by adding 10 and 15 to diastolic and systolic measures respectively.
Type 2 diabetes (T2D)
Type 2 diabetes cases were defined through self-report of diabetes using the baseline 
questionnaire. Cases were participants diagnosed at >35 years of age, and without reporting of 
insulin use within the first year of diagnosis (20). This resulted in 13,799 cases and 415,908 
controls (Table 1).
Metabolic predictors not available in the UK Biobank
Two measures of glycemic control were not measured in the UK Biobank at the time of study: 
fasting glucose (FG) and fasting insulin (FI).
For all continuous measurements in UK Biobank values more than 4.56SD away from the mean 
were excluded. These variables when then inverse normalised prior to analysis. 
The observational associations between the measured exposures and ACR were tested in UK 
Biobank using linear regression models, adjusted for age, sex and assessment centre. 
Genetic variants
For Mendelian randomization (MR) independent genetic variants were selected from the UK 
Biobank imputation dataset. Variants were excluded if imputation quality (INFO) was <0.3 or the 
minor allele frequency (MAF) was <0.1%.
The genetic variants for the exposure traits were selected based on published GWAS studies. 
Genetic variants were selected and extracted for the 11 metabolic markers including lipid levels 
(triglycerides, HDL-C and LDL-C), BMI, favourable adiposity (genetic variants associated with 
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9higher body fat percentage but lower risk of metabolic disease (e.g. type 2 diabetes, coronary 
heart disease)), WHR (adjusted for BMI), systolic and diastolic blood pressure, type 2 diabetes, 
fasting glucose and fasting insulin (Supplementary table 2). Four variants were identified that 
were previously identified to associate with ACR at genome wide significance: rs1047891 (HDL 
variant), rs4865796 (fasting insulin variant), rs109953111 (DBP variant) and rs2068888 
(triglyceride variant) (21). 
The extracted genetic variants were utilised to create genetic risk scores (GRS) for each 
metabolic trait of interest. The variants were weighted by their effect size (β-coefficient) obtained 
from the primary GWAS, where possible using GWAS that did not include data from the UK 
Biobank (equation 1). The weighted score was then rescaled to reflect the number of trait 
raising alleles (equation 2). 
 (Equation 1)𝑊𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 =  𝛽1 𝑥 𝑆𝑁𝑃1 + 𝛽2 𝑥 𝑆𝑁𝑃2 +…𝛽𝑛 𝑥 𝑆𝑁𝑃𝑛
 (Equation 2)𝑊𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒 =  𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 𝑥 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑁𝑃𝑠𝑠𝑢𝑚 𝑜𝑓 𝑡ℎ𝑒 𝛽 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠
Mendelian randomization
We used MR to test for causal relationships between our 11 metabolic risk factors as exposures 
and ACR as an outcome. MR relies on several assumptions as outlined in Figure 1:
● the exposure GRS are robustly associated with the relevant measured exposure 
(Supplementary table 1);
● the exposure GRS are not associated, independently of their effects on the exposure, 
with confounding factors that bias conventional epidemiological associations.
● the exposure GRS is only associated with the outcome via its effect on the modifiable 
exposure.  
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In this study, we employed several methods of MR: one and two-sample MR. The primary 
analyses utilised data from 438,075 UK Biobank participants with measured ACR. We extracted 
the genetic variants for the 11 known metabolic traits (Supplementary table 2) from the BOLT-
LMM (22) GWAS of ACR, which was adjusted for baseline age, sex, study centre, and 
genotyping array (0=BiLEVE, 1=Axiom UK Biobank interim release, 2=Axiom UK Biobank final 
release). We also extracted association statistics for the same SNPs from the largest GWAS of 
ACR (54,451 participants from CDKGen consortium meta-analysis, Teumer et al. 2016) which 
did not include the UK Biobank. 
Two-sample MR
Our primary MR approach was to use the inverse variance weighted (IVW) estimator. The IVW 
method involves a weighted regression of the effect sizes of variant-outcome associations 
against the effect sizes of the variant-risk factor associations constraining the intercept to zero. 
The beta coefficient from the weighted regression represents the standard deviation change in 
the ACR per SD change in the outcome variable (with the exception of type 2 diabetes, where 
we present our findings as an SD change in ACR per two-fold higher genetic liability for type 2 
diabetes). Several sensitivity analyses were performed to test whether the MR IVW estimates 
are biased by genetic variants that affect the outcome independently of the exposure of interest 
(i.e. horizontal pleiotropy). These methods were MR-Egger regression (23) and the weighted 
median (WM) estimator (24). MR-Egger is similar to IVW, except that the intercept is 
unconstrained. The intercept in MR-Egger reflects the average pleiotropic effect across genetic 
variants. Hence this method is less susceptible to potentially pleiotropic variants having a 
stronger effect on the outcome compared with their effect on the primary traits. The weighted 
median method is also more resistant to pleiotropy and gives consistent estimates even when 
50% of the variants are invalid. Given these different assumptions, if all methods are broadly 
consistent it strengthens our causal inference. The R code for the various 2-sample methods is 
available in (23; 24). 
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We performed sensitivity analyses for the four traits where one variant was known to be 
associated with ACR at genome-wide significance. Here, the 2-sample MR was repeated 
excluding that one variant.
The results from the 2-sample MR in the UK Biobank and the GWAS studies were meta-
analysed using the metan command in Stata. 
There is some overlap between the genetic variants for LDL-C, HDL-C and TG. Therefore, as 
well as individually exploring the role of the LDL-C, HDL-C and TG SNPs on the outcomes we 
also ran multivariate models adjusting for the other lipid associations (25). For example, when 
testing the causal role of LDL-C we included the LDL-C-SNP-TG association and the LDL-C-
SNP-HDL association as covariates in our model. 
One sample MR
In an unrelated subset of the data we also performed one-sample MR using the GRS and the 
ivreg2 command in STATA. In these models age, sex, ancestral principal components, 
assessment centre and genotyping platform were included as covariates. In cases where the 
predictor was not measured in the UK Biobank we explored the association of the GRS directly 
with the outcome. As with the two sample MR we performed multivariate analyses for the lipids 
by adjusting models for the other lipid GRS. For example, we performed MR to explore the 
causal role of LDL-C on ACR adjusting our models for all the standard covariates and the HDL-
C and TG GRS. 
Data and resource availability
The UK Biobank resource can be utilised by any bonafide researcher and access to all the 
genetic and phenotypic data utilised in this study are available upon application to the UK 
Biobank (https://www.ukbiobank.ac.uk/). The summary statistics from the CDKGEN are 
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available: (https://ckdgen.imbi.uni-freiburg.de). SUMMIT data utilised in this study are available 
on request to the Diabetes and Vascular Research Centre, University of Exeter Medical School. 
Results
Characteristics for the 438,075 UK Biobank and 743 SUMMIT participants are presented in 
table 1. 
SUMMIT provided evidence that supports the use of ACR as a marker of microvascular 
function
Results from the SUMMIT study support the use of ACR as a proxy for microvascular function 
with lower microvascular function associated with raised ACR levels. There was a negative 
association between ACR and skin microvascular function for both endothelium dependent 
(ACH) and independent (sodium nitroprusside) function. One SD lower response in endothelium 
dependent microvascular function as measured by skin reactivity to iontophoresis of ACH was 
associated with a 0.155 SD higher ACR (95%CI: 0.078, 0.230, p = 5.8E-05). One SD lower 
response in endothelium independent microvascular function as measured by reactivity to 
sodium nitroprusside was associated with a 0.206 SD higher ACR (95%CI: 0.131, 0.281, p = 
1.1E-07). Taken together these measures demonstrate that lower systemic microvascular 
response measured by skin reactivity to iontophoresis is associated with elevation in urinary 
ACR.
Observational associations for the 11 metabolic traits with ACR
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Data for observational analyses in UK Biobank were available for 9 of the 11 of exposure traits. 
Observational analyses provided evidence that higher HDL cholesterol, systolic and diastolic 
blood pressure, higher WHR adjusted for BMI and type 2 diabetes were associated with 
elevated ACR (Table 2). Higher LDL cholesterol, triglycerides, BMI and higher body fat 
percentage were associated with lower levels of ACR (Table 2). The inverse association 
between higher LDL cholesterol, triglycerides, BMI and higher body fat with lower ACR was 
unexpected, but maybe due to treatment effects, confounding or survival bias, thus highlighting 
the importance of more robust approaches, like MR.
Mendelian randomization finds a stronger causal role of triglycerides in elevating ACR 
compared to LDL-cholesterol
MR inferred a causal role of higher TG and LDL-C in elevating ACR, with the effect of TG more 
than twice that of LDL-C. A one-SD higher TG (approximately 86 mg/dl) was associated with a 
0.062 SD [95%CI: 0.040, 0.083] higher ACR (approximately 9.3 mg/mmol, Table 3, Figure 2), 
whilst a one-SD higher LDL-C (approximately 37 mg/dl) was associated with a 0.026 [95%CI: 
0.008, 0.044] SD higher ACR. There was no evidence to infer that higher HDL-C altered ACR. 
The evidence for a causal role of higher TG in elevating ACR was strengthened using 
multivariate MR which adjusted for the association of the TG SNPs with HDL-C and LDL-C. A 
one SD higher TG (adjusted for LDL-C and HDL-C) associated with a 0.094 SD [95%CI: 0.073, 
0.115] higher ACR (Figure 2, Supplementary table 3). In contrast, multivariate analyses 
attenuated the association between LDL-C and ACR, with a one SD higher LDL-C (adjusted for 
TG and HDL-C) associated with a 0.018 SD [95%CI: 0.001, 0.035] higher ACR (Figure 2, 
Supplementary table 3). There was no evidence that higher HDL-C adjusted for LDL-C and TG 
altered ACR.
Results were generally consistent when the more pleiotropy robust methods were utilised 
(Table 3). The estimates from the two studies (UK Biobank and CKDGen) and the one sample 
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MR in UK Biobank were consistent, strengthening the causal inference between triglycerides 
and ACR (Supplementary table 4, Supplementary figure 1). Findings for HDL and 
triglycerides were the same when variants known to be associated with ACR were excluded. 
Mendelian randomization finds causal role of body composition measures in elevating 
ACR
We next tested three measurements of body size and composition – BMI, waist hip ratio 
(adjusted for BMI) and metabolically “favourable adiposity”.  
The MR analyses suggested that higher WHR caused elevated ACR levels, independently of 
BMI. A one-SD higher WHR adjusted for BMI was associated with a 0.040 SD higher ACR 
([95%CI: 0.020, 0.059]; Table 3, Figure 3). 
MR using the “favourable adiposity” genetic variants (associated with higher body fat 
percentage but lower risk of metabolic diseases (26) showed that metabolically favourable 
higher adiposity was associated with lower ACR (-0.157 [95%CI: -0.256, -0.057], P=0.002; 
Figure 3). 
The MR results for higher BMI were not conclusive, although they were directionally consistent 
with the WHR results. 
Results from alternative MR methods (Table 3) and the study specific results from the UK 
Biobank, CKDGen and the one-sample MR results were generally consistent (Figure 3, 
Supplementary table 4). However, there was weak evidence of heterogeneity for BMI (P = 
0.013, I-squared 83.9%) and favourable adiposity (P = 0.027, I-squared 79.5%). 
Meta-analysis of two sample Mendelian randomization infers a causal role of type 2 
diabetes in elevating ACR  
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MR inferred that genetic liability to type 2 diabetes caused elevated ACR levels, with a two-fold 
higher genetic liability to type 2 diabetes associated with 0.013 SD [95%CI: 0.007, 0.018] higher 
ACR levels (Table 3, Figure 4). There was no evidence of a causal relationship between either 
fasting insulin or fasting glucose and ACR. 
Results were consistent when alternative MR methods were used (Table 3, Supplementary 
table 4) and when excluding the fasting insulin SNP that is also associated with ACR. The study 
specific results from the UK Biobank and CKDGen are presented in Supplementary table 4, 
Figure 4. .
Mendelian randomization confirms causal role of blood pressure in elevating ACR 
MR confirmed previous evidence (13) for the causal relationship between higher blood pressure 
and elevated ACR levels. A 1 mmHg higher systolic and diastolic blood pressure was causally 
associated with a 0.006 [95%CI: 0.004, 0.008] and 0.009 [95%CI: 0.006, 0.012] SD higher ACR 
respectively (Table 3, Figure 5).  
Results were consistent when alternative MR methods were used, although not all reached 
p<0.05 (Table 3). Excluding the one diastolic blood pressure variant that was associated with 
ACR in an independent study did not alter our findings. Study specific results from the UK 
Biobank, CKDGen and the one sample MR methods in the UK Biobank were generally 
consistent (Figure 5, Supplementary table 4), although there was evidence of heterogeneity 
for systolic blood pressure (P = 0.002, I-squared 89.6%). 
Discussion
This study used genetic approaches to infer the causal role of 11 metabolic risk factors on ACR, 
which was considered as a proxy for microvascular dysfunction.  Firstly, we confirmed that ACR 
is a valid proxy for microvascular function, using two gold standard physiological measures of 
microvascular function in the SUMMIT study – skin endothelial dependent and independent 
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microvascular function. We then used genetic variants as unconfounded proxies for the 11 
metabolic risk factors to infer that 7 of the 11 metabolic risk factors cause elevated levels of 
ACR and thus cause microvascular dysfunction. 
Skin microcirculation is an established model to investigate systemic microvascular function 
prior to the clinical manifestation of disease (27). Skin microvascular responses have been 
demonstrated to be reduced in people with type 2 diabetes (18) and associated with coronary 
microvascular function (28). Results presented here support the use of ACR as a proxy for the 
systemic microcirculation and not just for renal microcirculation.  
In keeping with the clinical data, we inferred a causal role of LDL cholesterol and triglycerides in 
raising ACR levels, with multivariate lipid analyses strengthening the triglyceride association and 
attenuating the LDL association. Indeed, the effect of triglycerides on ACR is twice as large as 
the effect of LDL. This contrasts with available evidence for coronary artery disease (CAD) 
where LDL levels have a larger effect on CAD risk than triglycerides. 
Whilst the effect sizes in our results can be seen as small, they represent clinically meaningful 
results. For example, previous studies have demonstrated that small changes in LDL 
cholesterol (e.g. 0.2 magnitude lower LDL in mmol/L) results in a 5 to 10% reduction in the risk 
of CHD (29). The majority of our analyses look at SD changes in ACR per genetically 
instrumented SD change in the predictor. For LDL, this equates to approximately a 0.9 mmol/L 
higher LDL, which in previous studies would equate to a 15 to 40% higher risk of CHD.
These results are consistent with those from clinical trials of cholesterol lowering medication. 
HMG Co-A reductase inhibitors (statins), predominantly lower LDL cholesterol, and have been 
demonstrated to reduce CAD risk. These drugs, however, only have a small effect on ACR (30), 
and a similarly small impact on other manifestations of microvascular dysfunction such as 
diabetic retinopathy (31). In contrast, PPARα antagonists such as fenofibrate, which act 
predominantly on triglyceride levels, have been shown to have beneficial effect on diabetic 
nephropathy and retinopathy (32). Combined statin-fenofibrate therapies can provide additional 
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endothelial vascular benefits than statin and fenofibrate alone (33) and, according to the recent 
results of the ACCORD study, it appears to be safe with regards to the risk of myositis or 
rhabdomyolysis when used in combination with a statin (34). Our results suggest that combined 
therapies lowering triglyceride as well as LDL levels could provide compound benefits by 
reducing the atherosclerotic burden, and thus CAD, whilst simultaneously reducing 
microvascular dysfunction which has a greater impact on the quality of life on patients (35).
We used three complementary measures of body composition to test the role of adiposity and 
body fat distribution on the ACR. These three measures were BMI, waist hip ratio (adjusted for 
BMI) as a measure of central adiposity and “favourable adiposity” as a measure of higher fat 
mass “uncoupled” from its adverse metabolic effects (26). Our MR analyses infer that higher 
WHR (adjusted for BMI) elevates ACR. In contrast, having more favourable adiposity alleles 
lowers ACR. The favourable adiposity variants are known to associate with higher 
subcutaneous fat, but lower liver fat and lower visceral-to-subcutaneous adipose tissue ratio 
(26).  This provides further evidence that body fat distribution may be important in albuminuria 
and microvascular problems. Previous studies have suggested a role for body fat distribution 
and visceral fat in albuminuria, although to date, these studies have had low numbers of 
participants and have only used observational data so are subject to more biases than the 
genetic approach employed in this study (10; 36; 37). A consistent trend was also noted for BMI, 
with higher BMI trending towards elevated ACR. These results suggest that adiposity and 
distribution of fat are important in elevating ACR and suggests a causal role for adiposity and fat 
distribution in microvascular dysfunction. 
Our analyses strengthen previous work demonstrating that higher systolic and diastolic blood 
pressure cause albuminuria (13). Our results confirmed the direction and magnitude of the MR 
inferred causal role of systolic and diastolic blood pressure on ACR recently reported (13) and 
support evidence from clinical trials showing that anti-hypertensive treatments acting on the 
Renin-angiotensin system reduce ACR (38). 
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As expected, our MR results confirm that diabetes plays a major role in raising ACR levels.  
These results add genetic evidence to the large body of data from observational studies and 
clinical trials clearly showing the role of T2D in causing renal damage. There was no genetic 
evidence for fasting insulin or fasting glucose levels causing elevated ACR levels. This is in 
contrast with observational studies showing an association between fasting insulin or fasting 
glucose and ACR levels (39; 40). This may indicate that these observational associations are 
driven by confounding factors. 
The major strength of this study is the availability of data in the UK Biobank and a large 
independent GWAS sample for testing the causal relationships using 2-sample MR approaches. 
Another strength is the use of multiple rigorous MR methods to establish causality in this 
analysis. MR provides the next best evidence of causality after randomized control trials and 
allow causal inferences on large scale databases such as those used in study.
We acknowledge, however, some limitations. Firstly, Mendelian randomization studies are not 
immune from some of the issues that affect observational studies. For example, it is possible 
that biases such as survival bias could have affected the MR as well as observational studies. If, 
for example, a high ACR and high LDL-cholesterol level results in a high mortality rate due to 
microvascular disease (e.g. stroke), then genetic factors that raise LDL-Cholesterol level could 
be depleted from the study and associations between LDL-cholesterol raising alleles and ACR 
could be weakened. This type of bias has been pointed out before (41). Secondly, our analyses 
were restricted to individuals of Caucasian descent and the UK Biobank is restricted to 
participants born between 1938 and 1971, therefore the generalisability of our findings may be 
limited. Thirdly, although multivariate MR was utilised to explore the role of the three lipids on 
ACR, there remains the potential for some residual bias due to the pleiotropic associations of 
the lipid variants, although more pleiotropy resistant methods generally provided consistent 
results. Finally, some of our instrumental variables explain only a small percentage of the 
variability of the outcome variable and therefore we might be underpowered to detect causal 
association in some of the analysis.
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In conclusion, we have utilised a genetic approach to show the causal role of 7 metabolic risk 
factors on ACR and provided evidence that dyslipidemia, adiposity and distribution of adipose 
tissue cause elevations in ACR and thus cause microvascular dysfunction. 
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Table 1. Participants’ characteristics. Data are presented as mean (±standard deviation) 
and median [25th -75th percentile] where not otherwise stated.
 UK Biobank SUMMIT
N 438,075 743
Age (yrs) 57.27 (± 8.02) 66.16 (± 8.82)
Sex [N males (%)] 237,181 (54.14%) 480 (64.60%)
Height (cm) 168.7 (± 9.2) 169.6 (± 0.09)
BMI 27.38 (± 4.75) 29.55 (± 5.22)
ACR (mg/mml) 1.10 [0.69 - 1.85] 0.70 [0.45 - 1.4]
CAD [N (%)] 36,434 (10.53%) 223 (30.01%)
T2D [N (%)] 13,799 (3.21%) 400 (53.84%)
Systolic BP (mmHg) 144.2 (± 24.0) 136.7 (16.5)
Diastolic BP (mmHg) 86.3 (± 13.5) 76.9 (8.71)
BMI = body mass index, ACR = albumin creatinine ratio, CAD = coronary arterial disease, 
available in 346,080 participants, T2D = type 2 diabetes, BP = blood pressure.
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Table 2. UK Biobank observational association results between investigated traits and ACR for 
observational data. 
Trait UK Biobank Beta* UK Biobank SE UK Biobank P
Diastolic BP 0.113 0.001 < 1.0E-15
Systolic BP 0.155 0.002 < 1.0E-15
HDL cholesterol 0.068 0.002 < 1.0E-15
LDL cholesterol -0.018 0.002 < 1.0E-15
Triglycerides -0.047 0.002 < 1.0E-15
BMI -0.106 0.001 < 1.0E-15
% Body fat -0.116 0.002 < 1.0E-15
Waist hip ratio (adjusted by BMI) 0.008 0.002 4.30E-07
Fasting glucose Not available Not available Not available
Fasting insulin Not available Not available Not available
T2D 0.353 0.008 < 1.0E-15
*Beta represents the standard deviation change in ACR per unit standard deviation change in 
continuous traits or change based on case-control status for binary traits. SE = standard error. 
BP = blood pressure, BMI = body mass index, T2D = type 2 diabetes, BP = blood pressure.
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Table 3. ACR results of meta analysis of Mendelian randomization results in UK Biobank and 
CKDGen. Betas represent standard deviation change in ACR for standard deviation change in 
metabolic trait, 95% confidence interval in brackets. 
       Main MR analysis Pleiotropy robust methods
Trait Beta IVW P IVW Beta Egger P Egger Beta WM P WM Beta PWM P PWM
Diastolic BP 0.009 (0.006, 0.012) 2.0E-09 -0.001 (-0.009, 0.008) 8.3E-01 0.009 (0.006, 0.012) 6.8E-10 0.008 (0.004, 0.011) 1.0E-05
Systolic BP 0.006 (0.004, 0.008) 3.8E-08 0.001 (-0.005, 0.007) 7.6E-01 0.006 (0.004, 0.007) 2.9E-09 0.005 (0.003, 0.008) 1.8E-06
HDL cholesterol -0.012 (-0.029, 0.006) 1.9E-01 0.012 (-0.013, 0.036) 3.5E-01 0.014 (-0.002, 0.030) 7.7E-01 0.014 (-0.009, 0.037) 2.5E-01
LDL cholesterol 0.026 (0.008, 0.044) 5.0E-03 0.022 (-0.006, 0.049) 1.2E-01 0.030 (0.014, 0.047) 2.6E-04 0.027 (0.009, 0.045) 3.8E-03
Triglycerides 0.062 (0.040, 0.083) 1.3E-08 0.064 (0.033, 0.096) 5.6E-05 0.050 (0.030, 0.070) 7.8E-07 0.054 (0.026, 0.082) 1.3E-04
BMI 0.024 (-0.002, 0.050) 7.3E-02 0.088 (0.031, 0.144) 2.3E-03 0.015 (-0.015, 0.045) 3.2E-01 0.033 (-0.002, 0.068) 6.1E-02
Favourable 
adiposity* -0.157 (-0.256, -0.057) 1.9E-03 0.082 (-0.017, 0.334) 5.2E-01 -0.143 (-0.230, -0.560) 1.3E-03 -0.143 (-0.266, -0.021) 2.1E-02
Waist hip ratio
(adjusted by BMI) 0.040 (0.020, 0.059) 6.3E-05 0.099 (0.051, 0.146) 4.9E-05 0.050 (0.027, 0.073) 2.0E-05 0.032 (0.008, 0.056) 8.0E-03
Fasting glucose -0.014 (-0.073, 0.044) 6.3E-01 -0.039 (-0.152, 0.074) 5.0E-01 -0.017 (-0.062, 0.028) 4.5E-01 -0.016 (-0.064, 0.032) 5.0E-01
Fasting insulin -0.018 (-0.215, 0.179) 8.6E-01 -1.318 (-2.409, -0.227) 1.8E-02 -0.035 (-0.159, 0.089) 5.8E-01 -0.032 (-0.170, 0.106) 6.5E-01
T2D liability 0.013 (0.006, 0.021) 5.2E-04 0.021 (0.006, 0.036) 7.6E-03 0.021 (0.012, 0.031) 1.4E-05 0.023 (0.011, 0.034) 1.1E-04
IVW = inverse variance weighted instrumental variable analysis, WM = weighted median 
analysis, PWM = penalised weighted median analysis.
BP = blood pressure, BMI = body mass index, T2D = type 2 diabetes.
*Favourable adiposity - represents higher adiposity but lower metabolic disease risk using 
genetic variants identified in Ji et al (26).
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When removing SNPs associated with ACR at genome wide significance the results were 
consistent with the previous results [Diastolic BP: Beta IVW = 0.069 (-0.050, 0.188), p = 7.5E-
10; HDL cholesterol: Beta IVW = 0.069 (-0.050, 0.188), p = 4.1E-02; Triglycerides: Beta IVW = 
0.057 (0.037, 0.077). p = 1.5E-08; Fasting Insulin: Beta IVW = 0.014 (-0.153, 0.181), p = 8.7E-
01]
Page 25 of 58 Diabetes
26
REFERENCES
1. Strain WD, Adingupu DD, Shore AC: Microcirculation on a large scale: techniques, tactics 
and relevance of studying the microcirculation in larger population samples. Microcirculation 
2012;19:37-46
2. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, 
Rashkow A, Joyce C, Nawaz S, Yusuf S, Investigators HS: Albuminuria and risk of 
cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 
2001;286:421-426
3. Strain WD, Shore AC, Melzer D: Albumin:creatinine ratio predicts mortality after stroke: 
analysis of the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 
2010;58:2434-2435
4. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, 
Jackson PG: Microalbuminuria and coronary heart disease in NIDDM: an incidence study. 
Diabetes 1998;47:1786-1792
5. Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: a meta-
analysis. J Am Soc Nephrol 2006;17:2006-2016
6. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic 
syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 
2011;6:2364-2373
7. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, Group UKPDS: Risks of 
progression of retinopathy and vision loss related to tight blood pressure control in type 2 
diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-1640
8. Buehler AM, Cavalcanti AB, Berwanger O, Figueiro M, Laranjeira LN, Zazula AD, Kioshi B, 
Bugano DG, Santucci E, Sbruzzi G, Guimaraes HP, Carvalho VO, Bordin SA: Effect of tight 
blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a 
systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther 
2013;31:147-160
Page 26 of 58Diabetes
27
9. Liese AD, Hense HW, Doring A, Stieber J, Keil U: Microalbuminuria, central adiposity and 
hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J 
Hum Hypertens 2001;15:799-804
10. Foster MC, Hwang SJ, Massaro JM, Hoffmann U, DeBoer IH, Robins SJ, Vasan RS, Fox 
CS: Association of subcutaneous and visceral adiposity with albuminuria: the Framingham 
Heart Study. Obesity (Silver Spring) 2011;19:1284-1289
11. Emdin CA, Khera AV, Natarajan P, Klarin D, Zekavat SM, Hsiao AJ, Kathiresan S: Genetic 
Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary 
Heart Disease. JAMA 2017;317:626-634
12. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G: Mendelian randomization: 
using genes as instruments for making causal inferences in epidemiology. Stat Med 
2008;27:1133-1163
13. Haas ME, Aragam KG, Emdin CA, Bick AG, International Consortium for Blood P, Hemani 
G, Davey Smith G, Kathiresan S: Genetic Association of Albuminuria with Cardiometabolic 
Disease and Blood Pressure. Am J Hum Genet 2018;103:461-473
14. Sobrin L, Chong YH, Fan Q, Gan A, Stanwyck LK, Kaidonis G, Craig JE, Kim J, Liao WL, 
Huang YC, Lee WJ, Hung YJ, Guo X, Hai Y, Ipp E, Pollack S, Hancock H, Price A, Penman A, 
Mitchell P, Liew G, Smith AV, Gudnason V, Tan G, Klein BEK, Kuo J, Li X, Christiansen MW, 
Psaty BM, Sandow K, Asian Genetic Epidemiology Network C, Jensen RA, Klein R, Cotch MF, 
Wang JJ, Jia Y, Chen CJ, Chen YI, Rotter JI, Tsai FJ, Hanis CL, Burdon KP, Wong TY, Cheng 
CY: Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A Mendelian 
Randomization Study. Diabetes 2017;66:3130-3141
15. Shore AC, Colhoun HM, Natali A, Palombo C, Khan F, Ostling G, Aizawa K, Kennback C, 
Casanova F, Persson M, Gooding K, Gates PE, Looker H, Dove F, Belch J, Pinnola S, Venturi 
E, Kozakova M, Goncalves I, Kravic J, Bjorkbacka H, Nilsson J, Consortium S: Use of Vascular 
Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The 
SUMMIT VIP Study. Diabetes Care 2018;41:2212-2219
16. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, 
Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen 
Page 27 of 58 Diabetes
28
N, Donnelly P, Marchini J: The UK Biobank resource with deep phenotyping and genomic data. 
Nature 2018;562:203-209
17. Tyrrell J, Mulugeta A, Wood AR, Zhou A, Beaumont RN, Tuke MA, Jones SE, Ruth KS, 
Yaghootkar H, Sharp S, Thompson WD, Ji Y, Harrison J, Freathy RM, Murray A, Weedon MN, 
Lewis C, Frayling TM, Hypponen E: Using genetics to understand the causal influence of higher 
BMI on depression. Int J Epidemiol 2018;
18. Casanova F, Adingupu DD, Adams F, Gooding KM, Looker HC, Aizawa K, Dove F, Elyas S, 
Belch JJF, Gates PE, Littleford RC, Gilchrist M, Colhoun HM, Shore AC, Khan F, Strain WD: 
The impact of cardiovascular co-morbidities and duration of diabetes on the association 
between microvascular function and glycaemic control. Cardiovasc Diabetol 2017;16:114
19. Teumer A, Tin A, Sorice R, Gorski M, Yeo NC, Chu AY, Li M, Li Y, Mijatovic V, Ko YA, 
Taliun D, Luciani A, Chen MH, Yang Q, Foster MC, Olden M, Hiraki LT, Tayo BO, Fuchsberger 
C, Dieffenbach AK, Shuldiner AR, Smith AV, Zappa AM, Lupo A, Kollerits B, Ponte B, Stengel 
B, Kramer BK, Paulweber B, Mitchell BD, Hayward C, Helmer C, Meisinger C, Gieger C, Shaffer 
CM, Muller C, Langenberg C, Ackermann D, Siscovick D, Dcct/Edic, Boerwinkle E, Kronenberg 
F, Ehret GB, Homuth G, Waeber G, Navis G, Gambaro G, Malerba G, Eiriksdottir G, Li G, 
Wichmann HE, Grallert H, Wallaschofski H, Volzke H, Brenner H, Kramer H, Mateo Leach I, 
Rudan I, Hillege HL, Beckmann JS, Lambert JC, Luan J, Zhao JH, Chalmers J, Coresh J, 
Denny JC, Butterbach K, Launer LJ, Ferrucci L, Kedenko L, Haun M, Metzger M, Woodward M, 
Hoffman MJ, Nauck M, Waldenberger M, Pruijm M, Bochud M, Rheinberger M, Verweij N, 
Wareham NJ, Endlich N, Soranzo N, Polasek O, van der Harst P, Pramstaller PP, Vollenweider 
P, Wild PS, Gansevoort RT, Rettig R, Biffar R, Carroll RJ, Katz R, Loos RJ, Hwang SJ, Coassin 
S, Bergmann S, Rosas SE, Stracke S, Harris TB, Corre T, Zeller T, Illig T, Aspelund T, Tanaka 
T, Lendeckel U, Volker U, Gudnason V, Chouraki V, Koenig W, Kutalik Z, O'Connell JR, Parsa 
A, Heid IM, Paterson AD, de Boer IH, Devuyst O, Lazar J, Endlich K, Susztak K, Tremblay J, 
Hamet P, Jacob HJ, Boger CA, Fox CS, Pattaro C, Kottgen A: Genome-wide Association 
Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes 2016;65:803-
817
Page 28 of 58Diabetes
29
20. Tyrrell JS, Yaghootkar H, Freathy RM, Hattersley AT, Frayling TM: Parental diabetes and 
birthweight in 236 030 individuals in the UK biobank study. Int J Epidemiol 2013;42:1714-1723
21. Casanova F, Tyrrell J, Beaumont RN, Ji Y, Jones SE, Hattersley AT, Weedon MN, Murray 
A, Shore AC, Frayling TM, Wood AR: A genome-wide association study implicates multiple 
mechanisms influencing raised urinary albumin-creatinine ratio. Hum Mol Genet 2019;
22. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem RM, Chasman 
DI, Ridker PM, Neale BM, Berger B, Patterson N, Price AL: Efficient Bayesian mixed-model 
analysis increases association power in large cohorts. Nat Genet 2015;47:284-290
23. Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid instruments: 
effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-525
24. Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in Mendelian 
Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet 
Epidemiol 2016;40:304-314
25. Burgess S, Thompson SG: Multivariable Mendelian randomization: the use of pleiotropic 
genetic variants to estimate causal effects. Am J Epidemiol 2015;181:251-260
26. Ji Y, Yiorkas AM, Frau F, Mook-Kanamori D, Staiger H, Thomas EL, Atabaki-Pasdar N, 
Campbell A, Tyrrell J, Jones SE, Beaumont RN, Wood AR, Tuke MA, Ruth KS, Mahajan A, 
Murray A, Freathy RM, Weedon MN, Hattersley AT, Hayward C, Machann J, Haring HU, Franks 
P, de Mutsert R, Pearson E, Stefan N, Frayling TM, Allebrandt KV, Bell JD, Blakemore AI, 
Yaghootkar H: Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically 
Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and 
Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension. Diabetes 2019;68:207-219
27. Holowatz LA, Thompson-Torgerson CS, Kenney WL: The human cutaneous circulation as a 
model of generalized microvascular function. J Appl Physiol (1985) 2008;105:370-372
28. Khan F, Patterson D, Belch JJ, Hirata K, Lang CC: Relationship between peripheral and 
coronary function using laser Doppler imaging and transthoracic echocardiography. Clin Sci 
(Lond) 2008;115:295-300
29. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss 
RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, 
Page 29 of 58 Diabetes
30
Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, 
Wiklund O, Stock JK, Chapman MJ, Catapano AL: Low-density lipoproteins cause 
atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical 
studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. 
Eur Heart J 2017;38:2459-2472
30. Verges B: Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol 
2005;16:648-651
31. Mansi I, Frei CR, Wang CP, Mortensen EM: Statins and New-Onset Diabetes Mellitus and 
Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults. J Gen Intern Med 
2015;30:1599-1610
32. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, 
Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, 
Ehnholm C, Laakso M, investigators Fs: Effects of long-term fenofibrate therapy on 
cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): 
randomised controlled trial. Lancet 2005;366:1849-1861
33. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK: Additive 
beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined 
hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653
34. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, 
Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff 
DC, Jr., Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in 
type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
35. Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Voko Z, Yabe D, Bluher M, Paldanius PM: 
Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. 
Diabetes Res Clin Pract 2014;105:302-312
36. de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, Steffes MW, 
Weiss NS, Brunzell JD, Diabetes C, Complications Trial/Epidemiology of Diabetes I, 
Complications Study Research G: Central obesity, incident microalbuminuria, and change in 
Page 30 of 58Diabetes
31
creatinine clearance in the epidemiology of diabetes interventions and complications study. J 
Am Soc Nephrol 2007;18:235-243
37. Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE, Group PS: A 
central body fat distribution is related to renal function impairment, even in lean subjects. Am J 
Kidney Dis 2003;41:733-741
38. Persson F, Lindhardt M, Rossing P, Parving HH: Prevention of microalbuminuria using early 
intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A 
systematic review. J Renin Angiotensin Aldosterone Syst 2016;17
39. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM: 
Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin 
resistance atherosclerosis study. Diabetes 1998;47:793-800
40. Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the 
metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952-958
41. Cohen JC, Stender S, Hobbs HH: APOC3, coronary disease, and complexities of Mendelian 
randomization. Cell Metab 2014;20:387-389
Page 31 of 58 Diabetes
Instrumental variables
GWAS of metabolic traits
Outcome
ACR
Exposures
Metabolic traits
Assumption 1
Genetic variants are 
associated with exposure
Assumption 3
Genetic variants influence risk of the outcome through 
the exposure, not through other pathways
Assumption 2
Genetic variants are not associated with confounders
Confounders
Unmediated association
Mediated association
Mediator
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Standard deviation diferences in ACR per standard deviation diferences in geneticaly instrumented
lipids measures
Page 33 of 58 Diabetes
For BMI and favourable adiposity there was evidence of heterogeneity (p = 0.013, I-squa-
red 83.9% and p = 0.027, I-squared 79.5%, respectively). No evidence of heterogeneity 
were found for WHR adjusted by BMI (p = 0.313, I-square 1.8%).
Standard deviation diferences in ACR per standard deviation diferences in geneticaly instrumented
adiposity measures.
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There was evidence of heterogeneity for type 2 diabetes (p = 0.004, I-squared 87.9%). There was no 
evidence of heterogeneity for for fasting glucose (p = 0.631, I-squared 0.0%) and fasting insulin (p = 
0.496, I-squared 0.0%).
Standard deviation diferences in ACR per standard deviation diferences in geneticaly instrumented
glycemic measures.
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Standard deviation diferences in ACR per standard deviation diferences in geneticaly instrumented
blood pressure.
There was no evidence of heterogeneity for diastolic blood pressure (p = 0.074, I-square 68.7%). 
Some evidence of heterogeneity were found for systolic blood pressure (p = 0.002, I-square 89.6%).
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Supplementary table 1. Strength of association of genetic instruments with measured exposure exposures.
Trait % variance F-statistic P 
Diastolic BP 2.17 9962 < 1.0E-15
Systolic BP 1.74 7966 < 1.0E-15
HDL cholesterol 6.4 26895 < 1.0E-15
LDL cholesterol 4.36 19550 < 1.0E-15
Triglycerides 4.91 22189 < 1.0E-15
BMI 1.6 7295 < 1.0E-15
Favourable adiposity 0.1 468 < 1.0E-15
Waist hip ratio (adjusted by BMI) 1.5 6837 < 1.0E-15
Fasting glucose Not available Not available
Fasting insulin Not available Not available
T2D 0.6 2504 < 1.0E-15
Supplementary table2. Genetic variants utilised in Mendelian randomization analyses. Gene location as reported by 
the original study (where available).
Trait
Genetic 
variant
Trait 
raising 
allele
Trait 
lowering 
allele
Beta  from 
the primary 
GWAS*
Primary GWAS* 
reference Gene Location
BODY MASS INDEX rs1000940 G A 0.019 Locke et al., 2014 RABEP1
BODY MASS INDEX rs10132280 C A 0.023 Locke et al., 2014 STXBP6
BODY MASS INDEX rs1016287 T C 0.023 Locke et al., 2014 FLJ30838
BODY MASS INDEX rs10182181 G A 0.031 Locke et al., 2014 ADCY3
BODY MASS INDEX rs10733682 A G 0.017 Locke et al., 2014 LMX1B
BODY MASS INDEX rs10938397 G A 0.04 Locke et al., 2014 GNPDA2
BODY MASS INDEX rs10968576 G A 0.025 Locke et al., 2014 LINGO2
BODY MASS INDEX rs11057405 G A 0.031 Locke et al., 2014 CLIP1
BODY MASS INDEX rs11126666 A G 0.021 Locke et al., 2014 KCNK3
BODY MASS INDEX rs11165643 T C 0.022 Locke et al., 2014 PTBP2
BODY MASS INDEX rs11191560 C T 0.031 Locke et al., 2014 NT5C2
BODY MASS INDEX rs11583200 C T 0.018 Locke et al., 2014 ELAVL4
BODY MASS INDEX rs1167827 G A 0.02 Locke et al., 2014 HIP1
BODY MASS INDEX rs11688816 G A 0.017 Locke et al., 2014 EHBP1
BODY MASS INDEX rs11727676 T C 0.036 Locke et al., 2014 HHIP
BODY MASS INDEX rs11847697 T C 0.049 Locke et al., 2014 PRKD1
BODY MASS INDEX rs12286929 G A 0.022 Locke et al., 2014 CADM1
BODY MASS INDEX rs12401738 A G 0.021 Locke et al., 2014 FUBP1
BODY MASS INDEX rs12429545 A G 0.033 Locke et al., 2014 OLFM4
BODY MASS INDEX rs12446632 G A 0.04 Locke et al., 2014 GPRC5B
BODY MASS INDEX rs12566985 G A 0.024 Locke et al., 2014 FPGT-TNNI3K
BODY MASS INDEX rs12885454 C A 0.021 Locke et al., 2014 PRKD1
BODY MASS INDEX rs12940622 G A 0.018 Locke et al., 2014 RPTOR
BODY MASS INDEX rs13021737 G A 0.06 Locke et al., 2014 TMEM18
BODY MASS INDEX rs13078960 G T 0.03 Locke et al., 2014 CADM2
BODY MASS INDEX rs13191362 A G 0.028 Locke et al., 2014 PARK2
BODY MASS INDEX rs1516725 C T 0.045 Locke et al., 2014 ETV5
BODY MASS INDEX rs1528435 T C 0.018 Locke et al., 2014 UBE2E3
BODY MASS INDEX rs1558902 A T 0.082 Locke et al., 2014 FTO
BODY MASS INDEX rs16851483 T G 0.048 Locke et al., 2014 RASA2
BODY MASS INDEX rs16951275 T C 0.031 Locke et al., 2014 MAP2K5
BODY MASS INDEX rs17001654 G C 0.031 Locke et al., 2014 SCARB2
BODY MASS INDEX rs17024393 C T 0.066 Locke et al., 2014 GNAT2
BODY MASS INDEX rs17094222 C T 0.025 Locke et al., 2014 HIF1AN
BODY MASS INDEX rs17405819 T C 0.022 Locke et al., 2014 HNF4G
BODY MASS INDEX rs17724992 A G 0.019 Locke et al., 2014 PGPEP1
BODY MASS INDEX rs1808579 C T 0.017 Locke et al., 2014 C18orf8
BODY MASS INDEX rs1928295 T C 0.019 Locke et al., 2014 TLR4
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BODY MASS INDEX rs2033529 G A 0.019 Locke et al., 2014 TDRG1
BODY MASS INDEX rs2033732 C T 0.019 Locke et al., 2014 RALYL
BODY MASS INDEX rs205262 G A 0.022 Locke et al., 2014 C6orf106
BODY MASS INDEX rs2075650 A G 0.026 Locke et al., 2014 TOMM40
BODY MASS INDEX rs2112347 T G 0.026 Locke et al., 2014 POC5
BODY MASS INDEX rs2121279 T C 0.025 Locke et al., 2014 LRP1B
BODY MASS INDEX rs2176598 T C 0.02 Locke et al., 2014 HSD17B12
BODY MASS INDEX rs2207139 G A 0.045 Locke et al., 2014 TFAP2B
BODY MASS INDEX rs2245368 C T 0.032 Locke et al., 2014 PMS2L11
BODY MASS INDEX rs2287019 C T 0.036 Locke et al., 2014 QPCTL
BODY MASS INDEX rs2365389 C T 0.02 Locke et al., 2014 FHIT
BODY MASS INDEX rs2650492 A G 0.021 Locke et al., 2014 SBK1
BODY MASS INDEX rs2820292 C A 0.02 Locke et al., 2014 NAV1
BODY MASS INDEX rs29941 G A 0.018 Locke et al., 2014 KCTD15
BODY MASS INDEX rs3101336 C T 0.033 Locke et al., 2014 NEGR1
BODY MASS INDEX rs3736485 A G 0.018 Locke et al., 2014 DMXL2
BODY MASS INDEX rs3810291 A G 0.028 Locke et al., 2014 ZC3H4
BODY MASS INDEX rs3817334 T C 0.026 Locke et al., 2014 MTCH2
BODY MASS INDEX rs3849570 A C 0.019 Locke et al., 2014 GBE1
BODY MASS INDEX rs4256980 G C 0.021 Locke et al., 2014 TRIM66
BODY MASS INDEX rs4740619 T C 0.018 Locke et al., 2014 C9orf93
BODY MASS INDEX rs543874 G A 0.048 Locke et al., 2014 SEC16B
BODY MASS INDEX rs6477694 C T 0.017 Locke et al., 2014 EPB41L4B
BODY MASS INDEX rs6567160 C T 0.056 Locke et al., 2014 MC4R
BODY MASS INDEX rs657452 A G 0.023 Locke et al., 2014 AGBL4
BODY MASS INDEX rs6804842 G A 0.019 Locke et al., 2014 RARB
BODY MASS INDEX rs7138803 A G 0.032 Locke et al., 2014 BCDIN3D
BODY MASS INDEX rs7141420 T C 0.024 Locke et al., 2014 NRXN3
BODY MASS INDEX rs7243357 T G 0.022 Locke et al., 2014 GRP
BODY MASS INDEX rs758747 T C 0.023 Locke et al., 2014 NLRC3
BODY MASS INDEX rs7599312 G A 0.022 Locke et al., 2014 ERBB4
BODY MASS INDEX rs7899106 G A 0.04 Locke et al., 2014 GRID1
BODY MASS INDEX rs9400239 C T 0.019 Locke et al., 2014 FOXO3
BODY MASS INDEX rs9581854 T C 0.03 Locke et al., 2014 MTIF3
BODY MASS INDEX rs9925964 A G 0.019 Locke et al., 2014 KAT8
DIASTOLIC BLOOD PRESSURE rs10850411 T C 0.253 Ehret et al. 2011 TBX3
DIASTOLIC BLOOD PRESSURE rs1173771 G A 0.261 Ehret et al. 2011 C5orf23, NPR3
DIASTOLIC BLOOD PRESSURE rs13082711 C T 0.238 Ehret et al. 2011 SLC4A7
DIASTOLIC BLOOD PRESSURE rs13139571 C A 0.26 Ehret et al. 2011 GUCY1A3, GUCY1B3
DIASTOLIC BLOOD PRESSURE rs1813353 T C 0.415 Ehret et al. 2011 CACNB2
DIASTOLIC BLOOD PRESSURE rs381815 T C 0.348 Ehret et al. 2011 PLEKHA7
DIASTOLIC BLOOD PRESSURE rs419076 T C 0.241 Ehret et al. 2011 MECOM
DIASTOLIC BLOOD PRESSURE rs4373814 C G 0.218 Ehret et al. 2011 CACNB2
DIASTOLIC BLOOD PRESSURE rs4590817 G C 0.419 Ehret et al. 2011 C10orf107
DIASTOLIC BLOOD PRESSURE rs6015450 G A 0.557 Ehret et al. 2011 EDN3, GNAS
DIASTOLIC BLOOD PRESSURE rs10077885 C A 0.174 Ehret et al. 2016 TRIM36
DIASTOLIC BLOOD PRESSURE rs11128722 G A 0.173 Ehret et al. 2016 FGD5
DIASTOLIC BLOOD PRESSURE rs11556924 C T 0.214 Ehret et al. 2016 ZC3HC1
DIASTOLIC BLOOD PRESSURE rs11953630 C T 0.281 Ehret et al. 2016 EBF1
DIASTOLIC BLOOD PRESSURE rs12627651 A G 0.204 Ehret et al. 2016 CRYAA, SIK1
DIASTOLIC BLOOD PRESSURE rs12940887 T C 0.27 Ehret et al. 2016 ZNF652
DIASTOLIC BLOOD PRESSURE rs12958173 A C 0.179 Ehret et al. 2016 SETBP1
DIASTOLIC BLOOD PRESSURE rs13107325 C T 0.684 Ehret et al. 2016 SLC39A8
DIASTOLIC BLOOD PRESSURE rs1327235 G A 0.308 Ehret et al. 2016 JAG1
DIASTOLIC BLOOD PRESSURE rs1361831 C T 0.271 Ehret et al. 2016 RSPO3
DIASTOLIC BLOOD PRESSURE rs1371182 C T 0.252 Ehret et al. 2016 FIGN, GRB14
DIASTOLIC BLOOD PRESSURE rs1450271 T C 0.199 Ehret et al. 2016 ADM
DIASTOLIC BLOOD PRESSURE rs1458038 T C 0.457 Ehret et al. 2016 FGF5
DIASTOLIC BLOOD PRESSURE rs1620668 G A 0.285 Ehret et al. 2016 ST7L, CAPZA1, MOV10
DIASTOLIC BLOOD PRESSURE rs17080093 C T 0.411 Ehret et al. 2016 PLEKHG1
DIASTOLIC BLOOD PRESSURE rs17638167 C T 0.348 Ehret et al. 2016 ELAVL3
DIASTOLIC BLOOD PRESSURE rs1799945 G C 0.457 Ehret et al. 2016 HFE
DIASTOLIC BLOOD PRESSURE rs1975487 G A 0.16 Ehret et al. 2016 PNPT1
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DIASTOLIC BLOOD PRESSURE rs2187668 C T 0.372 Ehret et al. 2016 BAT2, BAT5
DIASTOLIC BLOOD PRESSURE rs2291435 C T 0.156 Ehret et al. 2016 TBC1D1, FLJ13197
DIASTOLIC BLOOD PRESSURE rs2493134 C T 0.275 Ehret et al. 2016 AGT
DIASTOLIC BLOOD PRESSURE rs2521501 T A 0.359 Ehret et al. 2016 FURIN, FES
DIASTOLIC BLOOD PRESSURE rs2586886 C T 0.254 Ehret et al. 2016 KCNK3
DIASTOLIC BLOOD PRESSURE rs2891546 G A 0.38 Ehret et al. 2016 TBX5, TBX3
DIASTOLIC BLOOD PRESSURE rs2969070 G A 0.182 Ehret et al. 2016 CHST12, LFNG
DIASTOLIC BLOOD PRESSURE rs3184504 T C 0.448 Ehret et al. 2016 SH2B3
DIASTOLIC BLOOD PRESSURE rs3735533 C T 0.445 Ehret et al. 2016 HOTTIP, EVX
DIASTOLIC BLOOD PRESSURE rs3752728 A G 0.319 Ehret et al. 2016 PDE3A
DIASTOLIC BLOOD PRESSURE rs4245739 A C 0.243 Ehret et al. 2016 MDM4
DIASTOLIC BLOOD PRESSURE rs4247374 C T 0.385 Ehret et al. 2016 INSR
DIASTOLIC BLOOD PRESSURE rs592373 A G 0.282 Ehret et al. 2016 LSP1, TNNT3
DIASTOLIC BLOOD PRESSURE rs6271 C T 0.465 Ehret et al. 2016 DBH
DIASTOLIC BLOOD PRESSURE rs633185 C G 0.328 Ehret et al. 2016 FLJ32810, TMEM133
DIASTOLIC BLOOD PRESSURE rs6442101 T C 0.303 Ehret et al. 2016 MAP4
DIASTOLIC BLOOD PRESSURE rs6891344 A G 0.231 Ehret et al. 2016 CSNK1G3
DIASTOLIC BLOOD PRESSURE rs7103648 G A 0.241 Ehret et al. 2016
RAPSN, PSMC3, 
SLC39A13
DIASTOLIC BLOOD PRESSURE rs740746 A G 0.32 Ehret et al. 2016 ADRB1
DIASTOLIC BLOOD PRESSURE rs751984 T C 0.376 Ehret et al. 2016 LRRC10B
DIASTOLIC BLOOD PRESSURE rs772178 G A 0.208 Ehret et al. 2016 NCAPH
DIASTOLIC BLOOD PRESSURE rs880315 C T 0.257 Ehret et al. 2016 CASZ1
DIASTOLIC BLOOD PRESSURE rs918466 G A 0.182 Ehret et al. 2016 ADAMTS9
DIASTOLIC BLOOD PRESSURE rs932764 G A 0.224 Ehret et al. 2016 PLCE1
DIASTOLIC BLOOD PRESSURE rs943037 C T 0.482 Ehret et al. 2016 CYP17A1, NT5C2
DIASTOLIC BLOOD PRESSURE rs1060105 C T 0.182 Surendram et al. SBNO1
DIASTOLIC BLOOD PRESSURE rs10995311 C G 0.21 Surendram et al. ADO
DIASTOLIC BLOOD PRESSURE rs110419 A G 0.159 Surendram et al. LMO1
DIASTOLIC BLOOD PRESSURE rs1126464 C G 0.275 Surendram et al. DPEP1
DIASTOLIC BLOOD PRESSURE rs12521868 G T 0.191 Surendram et al. C5orf56
DIASTOLIC BLOOD PRESSURE rs1378942 C A 0.416 Surendram et al. CYP1A1-ULK3
DIASTOLIC BLOOD PRESSURE rs16851397 G A 0.375 Surendram et al. ZBTB38
DIASTOLIC BLOOD PRESSURE rs17249754 G A 0.522 Surendram et al. ATP2B1
DIASTOLIC BLOOD PRESSURE rs17367504 A G 0.547 Surendram et al. MTHFR, NPPB
DIASTOLIC BLOOD PRESSURE rs2304130 G A 0.292 Surendram et al. ZNF101
DIASTOLIC BLOOD PRESSURE rs2972146 T G 0.172 Surendram et al. Intergenic
DIASTOLIC BLOOD PRESSURE rs3774372 C T 0.367 Surendram et al. ULK4
DIASTOLIC BLOOD PRESSURE rs6095241 G A 0.168 Surendram et al. PREX1
DIASTOLIC BLOOD PRESSURE rs687621 A G 0.188 Surendram et al. ABO
DIASTOLIC BLOOD PRESSURE rs7302981 A G 0.249 Surendram et al. CERS5
DIASTOLIC BLOOD PRESSURE rs805303 G A 0.228 Surendram et al. BAT2, BAT5
DIASTOLIC BLOOD PRESSURE rs8068318 T C 0.262 Surendram et al. TBX2
DIASTOLIC BLOOD PRESSURE rs867186 A G 0.265 Surendram et al. PROCR
DIASTOLIC BLOOD PRESSURE rs10078021 G T 0.164 Warren et al. 2017 POC5
DIASTOLIC BLOOD PRESSURE rs1063281 C T 0.2 Warren et al. 2017 TNS1
DIASTOLIC BLOOD PRESSURE rs11030119 G A 0.163 Warren et al. 2017 BDNF
DIASTOLIC BLOOD PRESSURE rs12374077 C G 0.163 Warren et al. 2017 SENP2
DIASTOLIC BLOOD PRESSURE rs12405515 G T 0.165 Warren et al. 2017 DNM3
DIASTOLIC BLOOD PRESSURE rs12408022 T C 0.198 Warren et al. 2017 GPATCH2
DIASTOLIC BLOOD PRESSURE rs12906962 C T 0.221 Warren et al. 2017 chr15mb95
DIASTOLIC BLOOD PRESSURE rs12921187 G T 0.174 Warren et al. 2017 PPL
DIASTOLIC BLOOD PRESSURE rs13205180 T C 0.168 Warren et al. 2017 PKHD1
DIASTOLIC BLOOD PRESSURE rs143112823 G A 0.403 Warren et al. 2017 RP11- 439C8.2
DIASTOLIC BLOOD PRESSURE rs1438896 T C 0.234 Warren et al. 2017 TEX41
DIASTOLIC BLOOD PRESSURE rs2306374 C T 0.184 Warren et al. 2017 SCAF4
DIASTOLIC BLOOD PRESSURE rs2760061 A T 0.23 Warren et al. 2017 WNT3A
DIASTOLIC BLOOD PRESSURE rs2978098 A C 0.165 Warren et al. 2017 SNX31
DIASTOLIC BLOOD PRESSURE rs36022378 C T 0.202 Warren et al. 2017 CAMKV, ACTBP13
DIASTOLIC BLOOD PRESSURE rs4308 A G 0.213 Warren et al. 2017 ACE
DIASTOLIC BLOOD PRESSURE rs4364717 G A 0.175 Warren et al. 2017 MTAP
DIASTOLIC BLOOD PRESSURE rs4952611 C T 0.157 Warren et al. 2017 SLC8A1
DIASTOLIC BLOOD PRESSURE rs55701159 T G 0.285 Warren et al. 2017 ADCY3
Page 39 of 58 Diabetes
DIASTOLIC BLOOD PRESSURE rs6108168 C A 0.211 Warren et al. 2017 PLCB1
DIASTOLIC BLOOD PRESSURE rs62012628 C T 0.238 Warren et al. 2017 ADAMTS7
DIASTOLIC BLOOD PRESSURE rs62104477 T G 0.177 Warren et al. 2017 CCNE1
DIASTOLIC BLOOD PRESSURE rs62524579 G A 0.175 Warren et al. 2017 RP11-273G15.2
DIASTOLIC BLOOD PRESSURE rs6686889 T C 0.185 Warren et al. 2017 chr1mb25
DIASTOLIC BLOOD PRESSURE rs66887589 C T 0.215 Warren et al. 2017 PDE5A
DIASTOLIC BLOOD PRESSURE rs67330701 C T 0.367 Warren et al. 2017 MYEOV
DIASTOLIC BLOOD PRESSURE rs7178615 G A 0.179 Warren et al. 2017 RP11-321F6.1
DIASTOLIC BLOOD PRESSURE rs72799341 A G 0.185 Warren et al. 2017 FBXL19
DIASTOLIC BLOOD PRESSURE rs72812846 T A 0.209 Warren et al. 2017 CPEB4
DIASTOLIC BLOOD PRESSURE rs743757 C G 0.245 Warren et al. 2017 CACNA2D2
DIASTOLIC BLOOD PRESSURE rs745821 T G 0.189 Warren et al. 2017 MAPK4
DIASTOLIC BLOOD PRESSURE rs7592578 G T 0.24 Warren et al. 2017 TMEM194B
DIASTOLIC BLOOD PRESSURE rs76326501 A C 0.419 Warren et al. 2017 AC016735.1
DIASTOLIC BLOOD PRESSURE rs79146658 C NA 0.311 Warren et al. 2017 CCDC141
DIASTOLIC BLOOD PRESSURE rs8059962 C T 0.17 Warren et al. 2017 CMIP
DIASTOLIC BLOOD PRESSURE rs9372498 A T 0.334 Warren et al. 2017 SLC35F1
DIASTOLIC BLOOD PRESSURE rs953492 A G 0.22 Warren et al. 2017 SDCCAG8
DIASTOLIC BLOOD PRESSURE rs9827472 C T 0.177 Warren et al. 2017 FAM208A
FASTING GLUCOSE rs11715915 C T 0.012 Scott et al. 2012 AMT
FASTING GLUCOSE rs7651090 G A 0.013 Scott et al. 2012 IGF2BP2
FASTING GLUCOSE rs10747083 A G 0.013 Scott et al. 2012 P2RX2
FASTING GLUCOSE rs340874 C T 0.013 Scott et al. 2012 PROX1
FASTING GLUCOSE rs9368222 A C 0.014 Scott et al. 2012 CDKAL1
FASTING GLUCOSE rs2302593 C G 0.014 Scott et al. 2012 GIPR
FASTING GLUCOSE rs6943153 T C 0.015 Scott et al. 2012 GRB10
FASTING GLUCOSE rs10814916 C A 0.016 Scott et al. 2012
FASTING GLUCOSE rs6072275 A G 0.016 Scott et al. 2012 TOP1
FASTING GLUCOSE rs576674 G A 0.017 Scott et al. 2012 KL
FASTING GLUCOSE rs3783347 G T 0.017 Scott et al. 2012 WARS
FASTING GLUCOSE rs3829109 G A 0.017 Scott et al. 2012 DNLZ
FASTING GLUCOSE rs4869272 T C 0.018 Scott et al. 2012 PCSK1
FASTING GLUCOSE rs11603334 G A 0.019 Scott et al. 2012 ARAP1
FASTING GLUCOSE rs11619319 G A 0.02 Scott et al. 2012 PDX1
FASTING GLUCOSE rs174576 C A 0.02 Scott et al. 2012
FASTING GLUCOSE rs11607883 G A 0.021 Scott et al. 2012 CRY2
FASTING GLUCOSE rs7903146 T C 0.022 Scott et al. 2012 TCF7L2
FASTING GLUCOSE rs4502156 T C 0.022 Scott et al. 2012 VPS13C/C2CD4A/B
FASTING GLUCOSE rs11708067 A G 0.023 Scott et al. 2012 ADCY5
FASTING GLUCOSE rs11039182 T C 0.023 Scott et al. 2012 MADD
FASTING GLUCOSE rs10811661 T C 0.024 Scott et al. 2012 CDKN2B
FASTING GLUCOSE rs983309 T G 0.026 Scott et al. 2012 PPP1R3B
FASTING GLUCOSE rs1280 T C 0.026 Scott et al. 2012 SLC2A2
FASTING GLUCOSE rs780094 C T 0.027 Scott et al. 2012 GCKR
FASTING GLUCOSE rs11558471 A G 0.029 Scott et al. 2012
FASTING GLUCOSE rs2191349 T G 0.029 Scott et al. 2012 DGKB/TMEM195
FASTING GLUCOSE rs11195502 C T 0.032 Scott et al. 2012 ADRA2A
FASTING GLUCOSE rs6113722 G A 0.035 Scott et al. 2012 FOXA2
FASTING GLUCOSE rs16913693 T G 0.043 Scott et al. 2012 IKBKAP
FASTING GLUCOSE rs2908289 A G 0.057 Scott et al. 2012
FASTING GLUCOSE rs560887 C T 0.071 Scott et al. 2012 G6PC2
FASTING GLUCOSE rs10830963 G C 0.078 Scott et al. 2012 MTNR1B
FASTING INSULIN rs2972143 G A 0.014 Scott et al. 2012 IRS1
FASTING INSULIN rs2745353 T C 0.014 Scott et al. 2012 RSPO3
FASTING INSULIN rs1530559 A G 0.015 Scott et al. 2012 YSK4
FASTING INSULIN rs731839 G A 0.015 Scott et al. 2012 PEPD
FASTING INSULIN rs4865796 A G 0.015 Scott et al. 2012 ARL15
FASTING INSULIN rs2820436 C A 0.015 Scott et al. 2012 LYPLAL1
FASTING INSULIN rs1167800 A G 0.016 Scott et al. 2012 HIP1
FASTING INSULIN rs10195252 T C 0.016 Scott et al. 2012 GRB14
FASTING INSULIN rs9884482 C T 0.017 Scott et al. 2012 TET2
FASTING INSULIN rs860598 A G 0.018 Scott et al. 2012
FASTING INSULIN rs7903146 C T 0.018 Scott et al. 2012 TCF7L2
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FASTING INSULIN rs780094 C T 0.019 Scott et al. 2012 GCKR
FASTING INSULIN rs1421085 C T 0.02 Scott et al. 2012 FTO
FASTING INSULIN rs983309 T G 0.029 Scott et al. 2012 PPP1R3B
Favourable Adiposity rs11045172 C A 0.012 Ji et al. 2019 EBP2-PDE3A
Favourable Adiposity rs11118306 A G 0.023 Ji et al. 2019 LYPLAL1-SLC30A10
Favourable Adiposity rs13389219 T C 0.023 Ji et al. 2019 GRB14-COBLL1
Favourable Adiposity rs1801282 G C 0.031 Ji et al. 2019 PPARG
Favourable Adiposity rs2267373 C T 0.025 Ji et al. 2019 MAFF
Favourable Adiposity rs2276936 A C 0.016 Ji et al. 2019 FAM13A
Favourable Adiposity rs2943653 C T 0.032 Ji et al. 2019 NYAP2-IRS1
Favourable Adiposity rs2980888 C T 0.006 Ji et al. 2019 TRIB1--[
Favourable Adiposity rs40271 C T 0.021 Ji et al. 2019 ANKRD55-MAP3K1
Favourable Adiposity rs632057 G T 0.009 Ji et al. 2019 CITED2
Favourable Adiposity rs7133378 A G 0.026 Ji et al. 2019 DNAH10
Favourable Adiposity rs7258937 T C 0.015 Ji et al. 2019 PEPD
Favourable Adiposity rs972283 A G 0.017 Ji et al. 2019 KLF14-MKLN1
Favourable Adiposity rs998584 C A 0.016 Ji et al. 2019 VEGFA-C6orf223
HDL CHOLESTEROL rs1011731 A G 0.015 Liu et al. DNM3:Intron
HDL CHOLESTEROL rs1037378 G A 0.015 Liu et al. PDE3B:Intron
HDL CHOLESTEROL rs10483776 A G 0.02 Liu et al. FUT8:Intron
HDL CHOLESTEROL rs10861661 A C 0.017 Liu et al. RIC8B:Intron
HDL CHOLESTEROL rs10968576 A G 0.017 Liu et al. LINGO2:Intron
HDL CHOLESTEROL rs11553746 T C 0.015 Liu et al. ACP1:Thr95Ile
HDL CHOLESTEROL rs12055786 C T 0.021 Liu et al. RGS17:Intron
HDL CHOLESTEROL rs13379043 C T 0.017 Liu et al. C14orf43:Intron
HDL CHOLESTEROL rs146179438 C A 0.063 Liu et al. CDC25A:Gln25His
HDL CHOLESTEROL rs16928809 G A 0.029 Liu et al. SLC22A18:Intron
HDL CHOLESTEROL rs17189743 A G 0.04 Liu et al. TSPYL6:Arg246Cys
HDL CHOLESTEROL rs2074158 T C 0.02 Liu et al. DHX58:Gln425Arg
HDL CHOLESTEROL rs2303108 T C 0.015 Liu et al. ZC3H4:Intron
HDL CHOLESTEROL rs2785990 C T 0.015 Liu et al. LYPLAL1:Intergenic
HDL CHOLESTEROL rs28932178 C T 0.02 Liu et al. NSD1:Ser457Pro
HDL CHOLESTEROL rs35169799 C T 0.039 Liu et al. PLCB3:Ser778Leu
HDL CHOLESTEROL rs4871137 G T 0.022 Liu et al. KCND3:Intergenic
HDL CHOLESTEROL rs4976033 A G 0.015 Liu et al. IGFN1:Intergenic
HDL CHOLESTEROL rs622082 A G 0.017 Liu et al. IGHMBP2:Thr671Ala
HDL CHOLESTEROL rs7076938 T C 0.019 Liu et al. PLOD1:Intergenic
HDL CHOLESTEROL rs7136716 G A 0.021 Liu et al. AVPR1B:Intergenic
HDL CHOLESTEROL rs746463 C T 0.017 Liu et al. ZC3H12C:Intron
HDL CHOLESTEROL rs76116020 A G 0.041 Liu et al. TMED6:Phe6Leu
HDL CHOLESTEROL rs78074706 G A 0.053 Liu et al. ANKS3:Arg286Trp
HDL CHOLESTEROL rs8099014 A C 0.015 Liu et al. VPS13D:Intergenic
HDL CHOLESTEROL rs900399 G A 0.019 Liu et al. SEMA4A:Intergenic
HDL CHOLESTEROL rs9816226 T A 0.028 Liu et al. B4GALT3:Intergenic
HDL CHOLESTEROL rs10019888 A G 0.027 Willer et al. 2013 C4orf52
HDL CHOLESTEROL rs1047891 C C 0.027 Willer et al. 2013 CPS1
HDL CHOLESTEROL rs1121980 G A 0.02 Willer et al. 2013 FTO
HDL CHOLESTEROL rs11246602 C T 0.034 Willer et al. 2013 OR4C46
HDL CHOLESTEROL rs11613352 T C 0.028 Willer et al. 2013 LRP1
HDL CHOLESTEROL rs11869286 C G 0.032 Willer et al. 2013 STARD3
HDL CHOLESTEROL rs12145743 G T 0.02 Willer et al. 2013 HDGF, PMVK
HDL CHOLESTEROL rs12328675 C T 0.045 Willer et al. 2013 COBLL1
HDL CHOLESTEROL rs12678919 G A 0.155 Willer et al. 2013 LPL
HDL CHOLESTEROL rs12748152 C T 0.051 Willer et al. 2013 PIGV, NR0B2
HDL CHOLESTEROL rs12801636 A G 0.024 Willer et al. 2013 KAT5
HDL CHOLESTEROL rs12967135 G A 0.026 Willer et al. 2013 MC4R
HDL CHOLESTEROL rs13076253 A C 0.028 Willer et al. 2013 CPNE4
HDL CHOLESTEROL rs13107325 C T 0.071 Willer et al. 2013 SLC39A8
HDL CHOLESTEROL rs13326165 A G 0.029 Willer et al. 2013 STAB1
HDL CHOLESTEROL rs1532085 A G 0.107 Willer et al. 2013 LIPC
HDL CHOLESTEROL rs1689800 A G 0.034 Willer et al. 2013 ZNF648
HDL CHOLESTEROL rs16942887 A G 0.083 Willer et al. 2013 LCAT
HDL CHOLESTEROL rs17145738 T C 0.041 Willer et al. 2013 MLXIPL
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HDL CHOLESTEROL rs17173637 T C 0.036 Willer et al. 2013 TMEM176A
HDL CHOLESTEROL rs174546 C T 0.039 Willer et al. 2013 FADS1, FADS2, FADS3
HDL CHOLESTEROL rs17695224 G A 0.029 Willer et al. 2013 HAS1
HDL CHOLESTEROL rs1800961 C T 0.127 Willer et al. 2013 HNF4A
HDL CHOLESTEROL rs181362 C T 0.038 Willer et al. 2013 UBE2L3
HDL CHOLESTEROL rs1883025 C T 0.07 Willer et al. 2013 ABCA1
HDL CHOLESTEROL rs1936800 C T 0.02 Willer et al. 2013 RSPO3
HDL CHOLESTEROL rs2013208 T C 0.025 Willer et al. 2013 RBM5
HDL CHOLESTEROL rs2290547 G A 0.03 Willer et al. 2013 SETD2
HDL CHOLESTEROL rs2293889 G T 0.031 Willer et al. 2013 TRPS1
HDL CHOLESTEROL rs2602836 A G 0.019 Willer et al. 2013 ADH5
HDL CHOLESTEROL rs2606736 C T 0.025 Willer et al. 2013 ATG7
HDL CHOLESTEROL rs2652834 G A 0.029 Willer et al. 2013 LACTB
HDL CHOLESTEROL rs2923084 A G 0.026 Willer et al. 2013 AMPD3
HDL CHOLESTEROL rs2925979 C T 0.035 Willer et al. 2013 CMIP
HDL CHOLESTEROL rs2954029 T A 0.04 Willer et al. 2013 TRIB1
HDL CHOLESTEROL rs2972146 G T 0.032 Willer et al. 2013 IRS1
HDL CHOLESTEROL rs3136441 C T 0.055 Willer et al. 2013 LRP4
HDL CHOLESTEROL rs3764261 A C 0.241 Willer et al. 2013 CETP
HDL CHOLESTEROL rs3822072 G A 0.025 Willer et al. 2013 FAM13A
HDL CHOLESTEROL rs386000 C G 0.048 Willer et al. 2013 LILRA3
HDL CHOLESTEROL rs4129767 A G 0.024 Willer et al. 2013 PGS1
HDL CHOLESTEROL rs4142995 G T 0.026 Willer et al. 2013 SNX13
HDL CHOLESTEROL rs4148008 C G 0.028 Willer et al. 2013 ABCA8
HDL CHOLESTEROL rs4420638 A G 0.067 Willer et al. 2013 APOE
HDL CHOLESTEROL rs4650994 G A 0.021 Willer et al. 2013 ANGPTL1
HDL CHOLESTEROL rs4660293 A G 0.035 Willer et al. 2013 PABPC4
HDL CHOLESTEROL rs4731702 T C 0.029 Willer et al. 2013 KLF14
HDL CHOLESTEROL rs4759375 T C 0.056 Willer et al. 2013 SBNO1
HDL CHOLESTEROL rs4765127 T G 0.032 Willer et al. 2013 ZNF664
HDL CHOLESTEROL rs4846914 A G 0.048 Willer et al. 2013 GALNT2
HDL CHOLESTEROL rs4917014 G T 0.022 Willer et al. 2013 IKZF1
HDL CHOLESTEROL rs4983559 G A 0.02 Willer et al. 2013 ZBTB42, AKT1
HDL CHOLESTEROL rs499974 C A 0.026 Willer et al. 2013 MOGAT2, DGAT2
HDL CHOLESTEROL rs581080 C G 0.042 Willer et al. 2013 TTC39B
HDL CHOLESTEROL rs605066 T C 0.028 Willer et al. 2013 CITED2
HDL CHOLESTEROL rs6065906 T C 0.059 Willer et al. 2013 PLTP
HDL CHOLESTEROL rs6450176 G A 0.025 Willer et al. 2013 ARL15
HDL CHOLESTEROL rs6805251 T C 0.02 Willer et al. 2013 GSK3B
HDL CHOLESTEROL rs702485 G A 0.024 Willer et al. 2013 DAGLB
HDL CHOLESTEROL rs7134375 A C 0.021 Willer et al. 2013 PDE3A
HDL CHOLESTEROL rs7134594 T C 0.035 Willer et al. 2013 MVK
HDL CHOLESTEROL rs7241918 T G 0.09 Willer et al. 2013 LIPG
HDL CHOLESTEROL rs7255436 A C 0.032 Willer et al. 2013 ANGPTL4
HDL CHOLESTEROL rs731839 A G 0.022 Willer et al. 2013 PEPD
HDL CHOLESTEROL rs737337 T C 0.057 Willer et al. 2013 ANGPTL8
HDL CHOLESTEROL rs7941030 C T 0.028 Willer et al. 2013 UBASH3B
HDL CHOLESTEROL rs838880 C T 0.048 Willer et al. 2013 SCARB1
HDL CHOLESTEROL rs964184 C G 0.107 Willer et al. 2013 APOA1
HDL CHOLESTEROL rs970548 C A 0.026 Willer et al. 2013 MARCH8, ALOX5
HDL CHOLESTEROL rs998584 C A 0.026 Willer et al. 2013 VEGFA
HDL CHOLESTEROL rs9987289 G A 0.082 Willer et al. 2013 PPP1R3B
LDL CHOLESTEROL rs1016988 T C 0.02 Liu et al. CD101:Intergenic
LDL CHOLESTEROL rs10885997 G A 0.015 Liu et al. PNLIPRP2:Gln387Arg
LDL CHOLESTEROL rs11080150 A G 0.019 Liu et al. NF1:Intron
LDL CHOLESTEROL rs13146272 C A 0.015 Liu et al. CYP4V2:Gln259Lys
LDL CHOLESTEROL rs13379043 T C 0.018 Liu et al. C14orf43:Intron
LDL CHOLESTEROL rs147032017 C T 0.091 Liu et al. ZFPM1:Asp91Asp
LDL CHOLESTEROL rs1891110 A G 0.021 Liu et al. FAM24B:Pro2Leu
LDL CHOLESTEROL rs201148465 C A 0.21 Liu et al. HIST1H1B:Ala6Ala
LDL CHOLESTEROL rs201596848 C T 0.255 Liu et al. ZNF574:Arg734Cys
LDL CHOLESTEROL rs2076674 C T 0.018 Liu et al. SLC25A17:Intron
LDL CHOLESTEROL rs2125345 T C 0.024 Liu et al. UNK:Intron
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LDL CHOLESTEROL rs2239619 A C 0.018 Liu et al. HSPG2:Intergenic
LDL CHOLESTEROL rs28929474 T C 0.081 Liu et al. SERPINA1:Glu366Lys
LDL CHOLESTEROL rs351855 G A 0.018 Liu et al. FGFR4:Gly388Arg
LDL CHOLESTEROL rs3812594 G A 0.018 Liu et al. SEC16A:Arg1039Cys
LDL CHOLESTEROL rs4745 A T 0.015 Liu et al. EFNA1:Asp137Val
LDL CHOLESTEROL rs4809330 A G 0.015 Liu et al. ZGPAT:Intron
LDL CHOLESTEROL rs6062343 G A 0.014 Liu et al. TCEA2:Intron
LDL CHOLESTEROL rs61754230 T C 0.057 Liu et al. RAB21:Ser224Phe
LDL CHOLESTEROL rs635634 T C 0.069 Liu et al. IL6R:Intergenic
LDL CHOLESTEROL rs67710536 C A 0.028 Liu et al. RPS6:Utr3
LDL CHOLESTEROL rs6818397 T G 0.022 Liu et al. RGS12:Intron
LDL CHOLESTEROL rs704 A G 0.021 Liu et al. VTN:Thr400Met
LDL CHOLESTEROL rs77375493 G T 0.3 Liu et al. JAK2
LDL CHOLESTEROL rs9646133 G T 0.019 Liu et al. FLAD1:Intergenic
LDL CHOLESTEROL rs976002 G A 0.023 Liu et al. TMPRSS11E:Tyr303Cys
LDL CHOLESTEROL rs10102164 A G 0.032 Willer et al. 2013 SOX17
LDL CHOLESTEROL rs10401969 T C 0.118 Willer et al. 2013 CILP2
LDL CHOLESTEROL rs10490626 G A 0.051 Willer et al. 2013 INSIG2
LDL CHOLESTEROL rs11065987 A G 0.027 Willer et al. 2013 BRAP
LDL CHOLESTEROL rs11136341 G A 0.045 Willer et al. 2013 PLEC1
LDL CHOLESTEROL rs11220462 A G 0.059 Willer et al. 2013 ST3GAL4
LDL CHOLESTEROL rs11563251 T C 0.035 Willer et al. 2013 UGT1A1
LDL CHOLESTEROL rs1169288 C A 0.038 Willer et al. 2013 HNF1A
LDL CHOLESTEROL rs12027135 T A 0.03 Willer et al. 2013 LDLRAP1
LDL CHOLESTEROL rs1250229 C T 0.024 Willer et al. 2013 FN1
LDL CHOLESTEROL rs12670798 C T 0.034 Willer et al. 2013 DNAH11
LDL CHOLESTEROL rs12748152 T C 0.05 Willer et al. 2013 PIGV, NR0B2
LDL CHOLESTEROL rs12916 C T 0.073 Willer et al. 2013 HMGCR
LDL CHOLESTEROL rs1367117 A G 0.119 Willer et al. 2013 APOB
LDL CHOLESTEROL rs1564348 C T 0.048 Willer et al. 2013 LPA
LDL CHOLESTEROL rs17404153 G T 0.034 Willer et al. 2013 ACAD11
LDL CHOLESTEROL rs174546 C T 0.051 Willer et al. 2013 FADS1, FADS2, FADS3
LDL CHOLESTEROL rs1800562 G A 0.062 Willer et al. 2013 HFE
LDL CHOLESTEROL rs1801689 C A 0.103 Willer et al. 2013 APOH, PRXCA
LDL CHOLESTEROL rs2000999 A G 0.065 Willer et al. 2013 HPR
LDL CHOLESTEROL rs2030746 T C 0.021 Willer et al. 2013 LOC84931
LDL CHOLESTEROL rs2072183 C G 0.039 Willer et al. 2013 NPC1L1
LDL CHOLESTEROL rs2081687 T C 0.031 Willer et al. 2013 CYP7A1
LDL CHOLESTEROL rs2131925 T G 0.049 Willer et al. 2013 ANGPTL3
LDL CHOLESTEROL rs2255141 A G 0.03 Willer et al. 2013 GPAM
LDL CHOLESTEROL rs2328223 C A 0.03 Willer et al. 2013 SNX5
LDL CHOLESTEROL rs2479409 G A 0.064 Willer et al. 2013 PCSK9
LDL CHOLESTEROL rs2642442 T C 0.036 Willer et al. 2013 MOSC1
LDL CHOLESTEROL rs267733 A G 0.033 Willer et al. 2013 ANXA9, CERS2
LDL CHOLESTEROL rs2710642 A G 0.024 Willer et al. 2013 EHBP1
LDL CHOLESTEROL rs2902940 A G 0.027 Willer et al. 2013 MAFB
LDL CHOLESTEROL rs2954029 A T 0.056 Willer et al. 2013 TRIB1
LDL CHOLESTEROL rs314253 T C 0.024 Willer et al. 2013 DLG4
LDL CHOLESTEROL rs3177928 A G 0.045 Willer et al. 2013 HLA
LDL CHOLESTEROL rs364585 G A 0.025 Willer et al. 2013 SPTLC3
LDL CHOLESTEROL rs3757354 C T 0.038 Willer et al. 2013 MYLIP
LDL CHOLESTEROL rs3764261 C A 0.053 Willer et al. 2013 CETP
LDL CHOLESTEROL rs3780181 A G 0.045 Willer et al. 2013 VLDLR
LDL CHOLESTEROL rs4253776 G A 0.031 Willer et al. 2013 PPARA
LDL CHOLESTEROL rs4299376 G T 0.081 Willer et al. 2013 ABCG5, ABCG58
LDL CHOLESTEROL rs4420638 G A 0.225 Willer et al. 2013 APOE
LDL CHOLESTEROL rs4530754 A G 0.028 Willer et al. 2013 CSNK1G3
LDL CHOLESTEROL rs4722551 C T 0.039 Willer et al. 2013 MIR148A
LDL CHOLESTEROL rs4942486 T C 0.024 Willer et al. 2013 BRCA2
LDL CHOLESTEROL rs514230 T A 0.036 Willer et al. 2013 IRF2BP2
LDL CHOLESTEROL rs5763662 T C 0.077 Willer et al. 2013 MTMR3
LDL CHOLESTEROL rs6029526 A T 0.044 Willer et al. 2013 TOP1
LDL CHOLESTEROL rs629301 T G 0.167 Willer et al. 2013 SORT1
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LDL CHOLESTEROL rs6511720 G T 0.221 Willer et al. 2013 LDLR
LDL CHOLESTEROL rs6882076 C T 0.046 Willer et al. 2013 TIMD4
LDL CHOLESTEROL rs7206971 A G 0.029 Willer et al. 2013 OSBPL7
LDL CHOLESTEROL rs7640978 C T 0.039 Willer et al. 2013 CMTM6
LDL CHOLESTEROL rs8017377 A G 0.03 Willer et al. 2013 NYNRIN
LDL CHOLESTEROL rs9488822 A T 0.031 Willer et al. 2013 FRK
LDL CHOLESTEROL rs964184 G C 0.086 Willer et al. 2013 APOA1
LDL CHOLESTEROL rs9987289 G A 0.071 Willer et al. 2013 PPP1R3B
SYSTOLIC BLOOD PRESSURE rs1813353 T C 0.569 Ehret et al. 2011 CACNB2
SYSTOLIC BLOOD PRESSURE rs2932538 G A 0.388 Ehret et al. 2011 MOV10
SYSTOLIC BLOOD PRESSURE rs381815 T C 0.575 Ehret et al. 2011 PLEKHA7
SYSTOLIC BLOOD PRESSURE rs4373814 C G 0.373 Ehret et al. 2011 CACNB2
SYSTOLIC BLOOD PRESSURE rs4590817 G C 0.646 Ehret et al. 2011 C10orf107
SYSTOLIC BLOOD PRESSURE rs6015450 G A 0.896 Ehret et al. 2011 EDN3, GNAS
SYSTOLIC BLOOD PRESSURE rs7129220 A G 0.619 Ehret et al. 2011 ADM
SYSTOLIC BLOOD PRESSURE rs10077885 C A 0.284 Ehret et al. 2016 TRIM36
SYSTOLIC BLOOD PRESSURE rs10760117 T G 0.283 Ehret et al. 2016 PSMD5
SYSTOLIC BLOOD PRESSURE rs11128722 G A 0.31 Ehret et al. 2016 FGD5
SYSTOLIC BLOOD PRESSURE rs11556924 C T 0.271 Ehret et al. 2016 ZC3HC1
SYSTOLIC BLOOD PRESSURE rs1156725 C T 0.447 Ehret et al. 2016 PLEKHA7
SYSTOLIC BLOOD PRESSURE rs11953630 C T 0.412 Ehret et al. 2016 EBF1
SYSTOLIC BLOOD PRESSURE rs12247028 G A 0.364 Ehret et al. 2016 SYNPO2L
SYSTOLIC BLOOD PRESSURE rs12627651 A G 0.391 Ehret et al. 2016 CRYAA, SIK1
SYSTOLIC BLOOD PRESSURE rs12656497 C T 0.487 Ehret et al. 2016 NPR3, C5orf23
SYSTOLIC BLOOD PRESSURE rs12705390 A G 0.619 Ehret et al. 2016 PIK3C
SYSTOLIC BLOOD PRESSURE rs12940887 T C 0.362 Ehret et al. 2016 ZNF652
SYSTOLIC BLOOD PRESSURE rs12958173 A C 0.361 Ehret et al. 2016 SETBP1
SYSTOLIC BLOOD PRESSURE rs13107325 C T 0.837 Ehret et al. 2016 SLC39A8
SYSTOLIC BLOOD PRESSURE rs1327235 G A 0.395 Ehret et al. 2016 JAG1
SYSTOLIC BLOOD PRESSURE rs1361831 C T 0.482 Ehret et al. 2016 RSPO3
SYSTOLIC BLOOD PRESSURE rs1371182 C T 0.444 Ehret et al. 2016 FIGN, GRB14
SYSTOLIC BLOOD PRESSURE rs1458038 T C 0.659 Ehret et al. 2016 FGF5
SYSTOLIC BLOOD PRESSURE rs1620668 G A 0.535 Ehret et al. 2016 ST7L, CAPZA1, MOV10
SYSTOLIC BLOOD PRESSURE rs17010957 C T 0.498 Ehret et al. 2016 ARHGAP24
SYSTOLIC BLOOD PRESSURE rs17037390 G A 0.908 Ehret et al. 2016 MTHFR, NPPB
SYSTOLIC BLOOD PRESSURE rs17608766 C T 0.658 Ehret et al. 2016 GOSR2
SYSTOLIC BLOOD PRESSURE rs1799945 G C 0.627 Ehret et al. 2016 HFE
SYSTOLIC BLOOD PRESSURE rs2291435 C T 0.344 Ehret et al. 2016 TBC1D1, FLJ13197
SYSTOLIC BLOOD PRESSURE rs2493134 C T 0.413 Ehret et al. 2016 AGT
SYSTOLIC BLOOD PRESSURE rs2521501 T A 0.65 Ehret et al. 2016 FURIN, FES
SYSTOLIC BLOOD PRESSURE rs2586886 C T 0.404 Ehret et al. 2016 KCNK3
SYSTOLIC BLOOD PRESSURE rs2594992 C A 0.334 Ehret et al. 2016 HRH1, ATG7
SYSTOLIC BLOOD PRESSURE rs2898290 T C 0.377 Ehret et al. 2016 BLK, GATA4
SYSTOLIC BLOOD PRESSURE rs2969070 G A 0.298 Ehret et al. 2016 CHST12, LFNG
SYSTOLIC BLOOD PRESSURE rs3184504 T C 0.598 Ehret et al. 2016 SH2B3
SYSTOLIC BLOOD PRESSURE rs3735533 C T 0.798 Ehret et al. 2016 HOTTIP, EVX
SYSTOLIC BLOOD PRESSURE rs3741378 C T 0.486 Ehret et al. 2016 SIPA1
SYSTOLIC BLOOD PRESSURE rs4247374 C T 0.593 Ehret et al. 2016 INSR
SYSTOLIC BLOOD PRESSURE rs4691707 G A 0.349 Ehret et al. 2016 GUCY1A3, GUCY1B3
SYSTOLIC BLOOD PRESSURE rs592373 A G 0.484 Ehret et al. 2016 LSP1, TNNT3
SYSTOLIC BLOOD PRESSURE rs6271 C T 0.591 Ehret et al. 2016 DBH
SYSTOLIC BLOOD PRESSURE rs633185 C G 0.565 Ehret et al. 2016 FLJ32810, TMEM133
SYSTOLIC BLOOD PRESSURE rs6442101 T C 0.396 Ehret et al. 2016 MAP4
SYSTOLIC BLOOD PRESSURE rs6779380 C T 0.439 Ehret et al. 2016 MECOM
SYSTOLIC BLOOD PRESSURE rs6919440 G A 0.337 Ehret et al. 2016 ZNF318, ABCC10
SYSTOLIC BLOOD PRESSURE rs7103648 G A 0.335 Ehret et al. 2016 RAPSN, PSMC3, SLC39A13
SYSTOLIC BLOOD PRESSURE rs711737 A C 0.334 Ehret et al. 2016 SLC4A7
SYSTOLIC BLOOD PRESSURE rs7213273 G A 0.413 Ehret et al. 2016 PLCD3
SYSTOLIC BLOOD PRESSURE rs740746 A G 0.486 Ehret et al. 2016 ADRB1
SYSTOLIC BLOOD PRESSURE rs7515635 T C 0.307 Ehret et al. 2016 HIVEP3
SYSTOLIC BLOOD PRESSURE rs751984 T C 0.407 Ehret et al. 2016 LRRC10B
SYSTOLIC BLOOD PRESSURE rs880315 C T 0.475 Ehret et al. 2016 CASZ1
SYSTOLIC BLOOD PRESSURE rs932764 G A 0.495 Ehret et al. 2016 PLCE1
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SYSTOLIC BLOOD PRESSURE rs943037 C T 1.133 Ehret et al. 2016 CYP17A1, NT5C2
SYSTOLIC BLOOD PRESSURE rs1008058 A G 0.554 Surendram et al. PRDM6
SYSTOLIC BLOOD PRESSURE rs11229457 C T 0.312 Surendram et al. OR5B12
SYSTOLIC BLOOD PRESSURE rs1378942 C A 0.613 Surendram et al. CYP1A1-ULK3
SYSTOLIC BLOOD PRESSURE rs17249754 G A 0.928 Surendram et al. ATP2B1
SYSTOLIC BLOOD PRESSURE rs34591516 T C 0.636 Surendram et al. GPR20
SYSTOLIC BLOOD PRESSURE rs35529250 C T 1.537 Surendram et al. RBM47
SYSTOLIC BLOOD PRESSURE rs4387287 A C 0.338 Surendram et al. OBFC1
SYSTOLIC BLOOD PRESSURE rs4728142 G A 0.224 Surendram et al. Intergenic
SYSTOLIC BLOOD PRESSURE rs61760904 T C 1.499 Surendram et al. RRAS
SYSTOLIC BLOOD PRESSURE rs7406910 C T 0.456 Surendram et al. HOXB7
SYSTOLIC BLOOD PRESSURE rs805303 G A 0.376 Surendram et al. BAT2, BAT5
SYSTOLIC BLOOD PRESSURE rs9349379 A G 0.289 Surendram et al. PHACTR1
SYSTOLIC BLOOD PRESSURE rs10059921 G T 0.526 Warren et al. 2017 TMEM161B
SYSTOLIC BLOOD PRESSURE rs10922502 G A 0.382 Warren et al. 2017 GTF2B
SYSTOLIC BLOOD PRESSURE rs112184198 G A 0.659 Warren et al. 2017 PAX2
SYSTOLIC BLOOD PRESSURE rs11643209 G T 0.339 Warren et al. 2017 CFDP1
SYSTOLIC BLOOD PRESSURE rs12941318 C T 0.269 Warren et al. 2017 CRK
SYSTOLIC BLOOD PRESSURE rs13112725 C G 0.435 Warren et al. 2017 NPNT
SYSTOLIC BLOOD PRESSURE rs13238550 A G 0.331 Warren et al. 2017 MKLN1
SYSTOLIC BLOOD PRESSURE rs13420463 A G 0.356 Warren et al. 2017 PRKD3
SYSTOLIC BLOOD PRESSURE rs2467099 C T 0.307 Warren et al. 2017 ACOX1
SYSTOLIC BLOOD PRESSURE rs35199222 A G 0.322 Warren et al. 2017 ABHD17C
SYSTOLIC BLOOD PRESSURE rs3820068 A G 0.425 Warren et al. 2017 CELA2A
SYSTOLIC BLOOD PRESSURE rs55780018 C T 0.391 Warren et al. 2017 METTL21A, 
SYSTOLIC BLOOD PRESSURE rs6487543 A G 0.3 Warren et al. 2017 SSPN/ITPR2
SYSTOLIC BLOOD PRESSURE rs6595838 A G 0.344 Warren et al. 2017 FBN2
SYSTOLIC BLOOD PRESSURE rs6911827 T C 0.296 Warren et al. 2017 CASC15
SYSTOLIC BLOOD PRESSURE rs7562 T C 0.263 Warren et al. 2017 FOSL2
SYSTOLIC BLOOD PRESSURE rs78648104 C T 0.481 Warren et al. 2017 TFAP2D
SYSTOLIC BLOOD PRESSURE rs8016306 A G 0.335 Warren et al. 2017 PPP2R5E
SYSTOLIC BLOOD PRESSURE rs894344 G A 0.258 Warren et al. 2017 ZFAT
SYSTOLIC BLOOD PRESSURE rs9549328 T C 0.318 Warren et al. 2017 MCF2L
SYSTOLIC BLOOD PRESSURE rs9888615 C T 0.318 Warren et al. 2017 FERMT2
TRIGLYCERIDES rs1011731 G A 0.015 Liu et al. DNM3:Intron
TRIGLYCERIDES rs10861661 C A 0.019 Liu et al. RIC8B:Intron
TRIGLYCERIDES rs138358301 G A 0.15 Liu et al. SLC25A30:Phe280Leu
TRIGLYCERIDES rs26008 T C 0.028 Liu et al. FNIP1:Gln620Arg
TRIGLYCERIDES rs2785990 T C 0.016 Liu et al. LYPLAL1:Intergenic
TRIGLYCERIDES rs35169799 T C 0.038 Liu et al. PLCB3:Ser778Leu
TRIGLYCERIDES rs35665085 A G 0.032 Liu et al. CECR5:Thr149Met
TRIGLYCERIDES rs3769823 G A 0.017 Liu et al. CASP8:Lys14Arg
TRIGLYCERIDES rs3803357 C A 0.017 Liu et al. BAHD1:Gln298Lys
TRIGLYCERIDES rs3927680 T A 0.018 Liu et al. OR6P1:Intergenic
TRIGLYCERIDES rs3947 A G 0.024 Liu et al. CTSB:Utr3
TRIGLYCERIDES rs41274050 T C 0.1 Liu et al. A1CF:Gly398Ser
TRIGLYCERIDES rs41302559 G A 0.154 Liu et al. PCK1:Arg483Gln
TRIGLYCERIDES rs4976033 G A 0.018 Liu et al. IGFN1:Intergenic
TRIGLYCERIDES rs6062343 G A 0.018 Liu et al. TCEA2:Intron
TRIGLYCERIDES rs7157785 T G 0.023 Liu et al. NPR1:Intergenic
TRIGLYCERIDES rs7901016 C T 0.042 Liu et al. CCDC109A:Intron
TRIGLYCERIDES rs7946 C T 0.016 Liu et al. PEMT:Val212Met
TRIGLYCERIDES rs797486 A C 0.02 Liu et al. ADAR:Intergenic
TRIGLYCERIDES rs900399 A G 0.014 Liu et al. SEMA4A:Intergenic
TRIGLYCERIDES rs10401969 T C 0.121 Willer et al. 2013 CILP2
TRIGLYCERIDES rs10761731 A T 0.031 Willer et al. 2013 JMJD1C
TRIGLYCERIDES rs11613352 C T 0.028 Willer et al. 2013 LRP1
TRIGLYCERIDES rs11649653 C G 0.027 Willer et al. 2013 CTF1
TRIGLYCERIDES rs11776767 C G 0.022 Willer et al. 2013 PINX1
TRIGLYCERIDES rs1260326 T C 0.115 Willer et al. 2013 GCKR
TRIGLYCERIDES rs12678919 A G 0.17 Willer et al. 2013 LPL
TRIGLYCERIDES rs12748152 T C 0.037 Willer et al. 2013 PIGV, NR0B2
TRIGLYCERIDES rs13238203 C T 0.059 Willer et al. 2013 TYW1B
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TRIGLYCERIDES rs1495741 G A 0.04 Willer et al. 2013 NAT2
TRIGLYCERIDES rs1532085 A G 0.031 Willer et al. 2013 LIPC
TRIGLYCERIDES rs17145738 C T 0.115 Willer et al. 2013 MLXIPL
TRIGLYCERIDES rs174546 T C 0.045 Willer et al. 2013 FADS1, FADS2, FADS3
TRIGLYCERIDES rs1832007 A G 0.033 Willer et al. 2013 AKR1C4
TRIGLYCERIDES rs1936800 T C 0.018 Willer et al. 2013 RSPO3
TRIGLYCERIDES rs2068888 G A 0.024 Willer et al. 2013 CYP26A1
TRIGLYCERIDES rs2131925 T G 0.066 Willer et al. 2013 ANGPTL3
TRIGLYCERIDES rs2247056 C T 0.038 Willer et al. 2013 HLA-B
TRIGLYCERIDES rs2412710 A G 0.099 Willer et al. 2013 CAPN3
TRIGLYCERIDES rs2929282 T A 0.073 Willer et al. 2013 FRMD5
TRIGLYCERIDES rs2954029 A T 0.076 Willer et al. 2013 TRIB1
TRIGLYCERIDES rs2972146 T G 0.028 Willer et al. 2013 IRS1
TRIGLYCERIDES rs3198697 C T 0.02 Willer et al. 2013 PDXDC1
TRIGLYCERIDES rs3764261 C A 0.04 Willer et al. 2013 CETP
TRIGLYCERIDES rs38855 A G 0.019 Willer et al. 2013 MET
TRIGLYCERIDES rs442177 T G 0.031 Willer et al. 2013 KLHL8
TRIGLYCERIDES rs4719841 G A 0.023 Willer et al. 2013 MIR148A
TRIGLYCERIDES rs4765127 G T 0.029 Willer et al. 2013 ZNF664
TRIGLYCERIDES rs4846914 G A 0.04 Willer et al. 2013 GALNT2
TRIGLYCERIDES rs5756931 T C 0.02 Willer et al. 2013 PLA2G6
TRIGLYCERIDES rs6065906 C T 0.053 Willer et al. 2013 PLTP
TRIGLYCERIDES rs645040 T G 0.029 Willer et al. 2013 MSL2L1
TRIGLYCERIDES rs6831256 G A 0.026 Willer et al. 2013 LRPAP1
TRIGLYCERIDES rs6882076 C T 0.029 Willer et al. 2013 TIMD4
TRIGLYCERIDES rs7248104 G A 0.022 Willer et al. 2013 INSR
TRIGLYCERIDES rs731839 G A 0.022 Willer et al. 2013 PEPD
TRIGLYCERIDES rs8077889 C A 0.025 Willer et al. 2013 MPP3
TRIGLYCERIDES rs964184 G C 0.234 Willer et al. 2013 APOA1
TRIGLYCERIDES rs9686661 T C 0.038 Willer et al. 2013 MAP3K1
TRIGLYCERIDES rs9930333 G T 0.021 Willer et al. 2013 FTO
TRIGLYCERIDES rs998584 A C 0.029 Willer et al. 2013 VEGFA
TRIGLYCERIDES rs6054 T C 0.14 Liu et al. FGB:Pro206Leu
TYPE 2 DIABETES rs17867832 T G 0.086177696 Cho et al. 2011 GRM8
TYPE 2 DIABETES rs3734621 C A 0.067658648 Cho et al. 2011 KIF6
TYPE 2 DIABETES rs3786897 A G 0.029558802 Cho et al. 2011 PEPD
TYPE 2 DIABETES rs831571 C T 0.029558802 Cho et al. 2011 PSMD6
TYPE 2 DIABETES rs9470794 T C 0.009950331 Cho et al. 2011 ZFND3
TYPE 2 DIABETES rs2233580 T C 0.58221562 Fuchsberger et al. 2016 PAX4
TYPE 2 DIABETES rs6813195 C T 0.086177696 Harder et al. 2015 TMEM154
TYPE 2 DIABETES rs10278336 A G 0.067658648 Kong et al. 2009 MOB2
TYPE 2 DIABETES rs12242953 G A 0.067658648 Kooner et al. 2011 SRGN
TYPE 2 DIABETES rs16861329 C T 0.029558802 Kooner et al. 2011 ST6GAL1
TYPE 2 DIABETES rs2007084 G A 0.019802627 Kooner et al. 2011 ANPEP
TYPE 2 DIABETES rs4812829 A G 0.058268908 Kooner et al. 2011 HNF4A
TYPE 2 DIABETES rs10401969 C T 0.122217633 Morris et al. 2012 CILP2
TYPE 2 DIABETES rs10758593 A G 0.058268908 Morris et al. 2012 GLIS3
TYPE 2 DIABETES rs10811661 T C 0.165514438 Morris et al. 2012 CDKN2A/B
TYPE 2 DIABETES rs10830963 G C 0.09531018 Morris et al. 2012 MTNR1B
TYPE 2 DIABETES rs10842994 C T 0.09531018 Morris et al. 2012 KLHDC5
TYPE 2 DIABETES rs10923931 T G 0.076961041 Morris et al. 2012 NOTCH2
TYPE 2 DIABETES rs1111875 C T 0.104360015 Morris et al. 2012 HHEX, IDE
TYPE 2 DIABETES rs11257655 T C 0.067658648 Morris et al. 2012 CDC123/CAMK1D
TYPE 2 DIABETES rs11634397 G A 0.048790164 Morris et al. 2012 ZFAND6
TYPE 2 DIABETES rs11651052 A G 0.09531018 Morris et al. 2012 HNF1B
TYPE 2 DIABETES rs11717195 T C 0.104360015 Morris et al. 2012 ADCY5
TYPE 2 DIABETES rs12427353 G C 0.076961041 Morris et al. 2012 HNF1A
TYPE 2 DIABETES rs12571751 A G 0.076961041 Morris et al. 2012 ZMIZ1
TYPE 2 DIABETES rs12899811 G A 0.076961041 Morris et al. 2012 PRC1
TYPE 2 DIABETES rs12970134 A G 0.076961041 Morris et al. 2012 MC4R
TYPE 2 DIABETES rs13389219 C T 0.067658648 Morris et al. 2012 GRB14
TYPE 2 DIABETES rs1359790 G A 0.076961041 Morris et al. 2012 SPRY2
TYPE 2 DIABETES rs1496653 A G 0.086177696 Morris et al. 2012 UBE2E2
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TYPE 2 DIABETES rs1552224 A C 0.104360015 Morris et al. 2012 ARAP1
TYPE 2 DIABETES rs163184 G T 0.086177696 Morris et al. 2012 KCNQ1
TYPE 2 DIABETES rs17168486 T C 0.104360015 Morris et al. 2012 DGKB
TYPE 2 DIABETES rs17791513 A G 0.113328685 Morris et al. 2012 TLE4
TYPE 2 DIABETES rs1801282 C G 0.122217633 Morris et al. 2012 PPARG
TYPE 2 DIABETES rs2075423 G T 0.067658648 Morris et al. 2012 PROX1
TYPE 2 DIABETES rs2261181 T C 0.122217633 Morris et al. 2012 HMGA2
TYPE 2 DIABETES rs243088 T A 0.067658648 Morris et al. 2012 BCL11A
TYPE 2 DIABETES rs2796441 G A 0.067658648 Morris et al. 2012 TLE1
TYPE 2 DIABETES rs2943640 C A 0.09531018 Morris et al. 2012 IRS1
TYPE 2 DIABETES rs3802177 G A 0.131028262 Morris et al. 2012 SLC30A8
TYPE 2 DIABETES rs4402960 T G 0.122217633 Morris et al. 2012 IGF2BP2
TYPE 2 DIABETES rs4458523 G T 0.09531018 Morris et al. 2012 WFS1
TYPE 2 DIABETES rs4502156 T C 0.058268908 Morris et al. 2012 C2CD4A
TYPE 2 DIABETES rs459193 G A 0.076961041 Morris et al. 2012 ANKRD55
TYPE 2 DIABETES rs516946 C T 0.086177696 Morris et al. 2012 ANK1
TYPE 2 DIABETES rs5215 C T 0.067658648 Morris et al. 2012 KCNJ11
TYPE 2 DIABETES rs6795735 C T 0.076961041 Morris et al. 2012 ADAMTS9
TYPE 2 DIABETES rs6878122 G A 0.09531018 Morris et al. 2012 ZBED3
TYPE 2 DIABETES rs7177055 A G 0.076961041 Morris et al. 2012 HMG20A
TYPE 2 DIABETES rs7202877 T G 0.113328685 Morris et al. 2012 BCAR1
TYPE 2 DIABETES rs7756992 G A 0.157003749 Morris et al. 2012 CDKAL1
TYPE 2 DIABETES rs7845219 T C 0.058268908 Morris et al. 2012 TP53INP1
TYPE 2 DIABETES rs7903146 T C 0.329303747 Morris et al. 2012 TCF7L2
TYPE 2 DIABETES rs7955901 C T 0.067658648 Morris et al. 2012 TSPAN8, LGR5
TYPE 2 DIABETES rs8108269 G T 0.067658648 Morris et al. 2012 GIPR
TYPE 2 DIABETES rs849135 G A 0.104360015 Morris et al. 2012 JAZF1
TYPE 2 DIABETES rs9936385 C T 0.122217633 Morris et al. 2012 FTO
TYPE 2 DIABETES rs2334499 T C 0.039220713 PMID: 20016592
TYPE 2 DIABETES rs7593730 C T 0.104360015 Qi et al. 2010 RBMS1/ITGB6
TYPE 2 DIABETES rs76895963 T G 0.634878032 Steinthorsdottir et al. 2014 CCND2
TYPE 2 DIABETES rs16927668 T C 0.039220713 Tsai et al. 2010 PTPRD
TYPE 2 DIABETES rs2447090 A G 0.039220713 Tsai et al. 2010 MNT
TYPE 2 DIABETES rs13233731 G A 0.048790164 Voight et al. 2010 KLF14
WAIST HIP RATIO (ADJUSTED BY BMI) rs10049088 C miss 0.029 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10054063 T miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10055995 C miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10100423 T miss 0.042 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10100533 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10249651 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1029472 G miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1029645 G miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1035942 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1045241 C miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10462028 A miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10463416 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10502148 C miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10507524 C miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1051684 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1057119 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10745659 G miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10778504 T miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10799424 T miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10808546 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10817896 T miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10820747 A miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10827226 T miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10842707 T miss 0.034 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10843804 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10878367 A miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10880823 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10887759 A miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10913257 G miss 0.011 Pulit et al. 2019 Not available
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WAIST HIP RATIO (ADJUSTED BY BMI) rs10919388 C miss 0.033 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10923724 T miss 0.035 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10963067 C miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs10980797 G miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11042077 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1105881 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11074934 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11078594 G miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11082430 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11085744 T miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11088991 T miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1111875 C miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11129657 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11134029 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11187537 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11204762 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11205773 T miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11235 C miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs112907088 G miss 0.041 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1139653 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1144 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs114760566 A miss 0.093 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11574514 C miss 0.029 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11592754 C miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11670056 C miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11722554 G miss 0.033 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11724804 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11746028 C miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11747001 A miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11757455 G miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11770285 C miss 0.031 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11786566 G miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs11897119 C miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1190982 T miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12138803 T miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1223581 T miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12325187 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12419064 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12435790 A miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12441543 G miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12442323 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12454712 T miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12459350 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12494105 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1250259 T miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12527712 T miss 0.034 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12543555 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12608426 A miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12608504 A miss 0.026 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12684047 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12686771 T miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12692387 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12694042 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12774134 C miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12823266 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs12828318 A miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1294432 T miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13010546 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13107325 C miss 0.031 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13137905 T miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13198178 C miss 0.031 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13223034 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13234914 G miss 0.013 Pulit et al. 2019 Not available
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WAIST HIP RATIO (ADJUSTED BY BMI) rs13256367 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1328757 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1334576 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs13379794 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1345203 T miss 0.026 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1364422 T miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1385167 G miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs139271800 A miss 0.239 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs140201358 G miss 0.085 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1406948 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs144033177 C miss 0.053 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1440372 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs144926207 T miss 0.032 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs145878042 A miss 0.081 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs146182298 T miss 0.031 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1481801 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1485745 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1494204 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs149921263 A miss 0.04 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs150841499 C miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1511022 T miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1522811 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1541681 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1561 T miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1569135 A miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1635853 T miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs16907277 G miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs16976826 T miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs16978854 G miss 0.033 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17067999 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17101456 G miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17154889 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17289035 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17311057 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17326656 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17369710 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17417407 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs174829 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17509001 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17511102 T miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1757471 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17703354 C miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17703883 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs17764730 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1800978 C miss 0.026 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1805740 G miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs180958337 T miss 0.088 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1893781 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1979527 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs1997833 C miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2012485 C miss 0.029 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2027982 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2028386 G miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2047937 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2061708 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2075665 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2124307 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2145272 G miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2158828 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2167750 T miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2200155 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2222543 G miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2236519 A miss 0.03 Pulit et al. 2019 Not available
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WAIST HIP RATIO (ADJUSTED BY BMI) rs2272790 G miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2277339 G miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs227733 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2279469 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2294239 A miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2294823 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2299253 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2373078 T miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2376585 C miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2387280 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2398893 A miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2503100 G miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2524163 T miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2526886 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2529411 G miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2595004 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2602680 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2603229 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2701523 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs270960 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2786198 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2791550 G miss 0.037 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2836141 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs28408682 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs28451064 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2898237 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2925979 T miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2970332 A miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs299615 G miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs2997447 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3110697 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3218121 A miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs322396 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs332105 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs34000 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs34312154 A miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs34905952 A miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs352300 C miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs35344256 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs35419826 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs35710478 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs357438 G miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3731861 C miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3741378 C miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3757298 C miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3761706 A miss 0.032 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3786897 G miss 0.028 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3792751 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3803042 A miss 0.027 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3807947 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3851294 G miss 0.026 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs3936510 T miss 0.03 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs402294 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs41277978 A miss 0.073 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4293945 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4371408 A miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4372913 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4420638 A miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4474021 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4489410 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4558863 C miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4646342 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4684857 C miss 0.021 Pulit et al. 2019 Not available
Page 50 of 58Diabetes
WAIST HIP RATIO (ADJUSTED BY BMI) rs4686696 A miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4773173 A miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4789261 C miss 0.029 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4794033 G miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4902630 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4951588 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4964058 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs4964656 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs541091 G miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs55747707 G miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs55920843 T miss 0.086 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs56185013 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs56196860 C miss 0.036 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs56271783 C miss 0.059 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs598104 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs59888683 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6018291 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6040229 G miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6047259 T miss 0.01 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6054471 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs62012773 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs62070804 T miss 0.047 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs62271373 A miss 0.041 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs62621197 C miss 0.036 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs634869 T miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6426912 T miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6432188 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6480914 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6556301 T miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs664532 T miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6658424 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6688233 T miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6705646 A miss 0.025 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6721459 G miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6752964 C miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6795831 A miss 0.035 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6853254 T miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6859752 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6867518 C miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6872807 T miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6905288 A miss 0.044 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6932767 T miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6940715 A miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs6985478 A miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs699370 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7003062 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7020604 A miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7070749 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7086377 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7102 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs711076 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs711869 G miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7119797 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs71439172 G miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs71511786 A miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs715300 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs717795 C miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7198287 C miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7213608 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7225453 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7235010 A miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7252102 G miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs727428 T miss 0.016 Pulit et al. 2019 Not available
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WAIST HIP RATIO (ADJUSTED BY BMI) rs7279347 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs72823057 C miss 0.029 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs72877579 C miss 0.035 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs72959041 A miss 0.162 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs73001065 C miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs73094710 T miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7350438 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs73858966 A miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs73942938 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7395513 G miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs740838 C miss 0.043 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs747249 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7492628 G miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7521902 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7530102 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7554947 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs755643 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs757081 G miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs757608 A miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7585974 C miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7680787 T miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7708285 G miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7721054 T miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7744833 A miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7795371 A miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7798002 T miss 0.032 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs780159 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7827182 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7854560 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7903146 T miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7932891 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7945962 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs79664277 A miss 0.021 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs797486 A miss 0.037 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs7993238 C miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs801593 G miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8024294 A miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8054299 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs805768 T miss 0.018 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8066985 A miss 0.023 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8074638 A miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8080903 C miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8103017 G miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8126001 C miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs8142329 G miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs821100 G miss 0.016 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs848286 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs863750 T miss 0.037 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs889129 T miss 0.02 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs905938 T miss 0.024 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs910071 C miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs910382 G miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs917191 C miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs917681 T miss 0.012 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs930653 A miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9341990 A miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9388766 C miss 0.017 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9415106 A miss 0.014 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9435732 C miss 0.013 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs951252 G miss 0.019 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9644033 A miss 0.022 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9647379 G miss 0.015 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9678859 A miss 0.019 Pulit et al. 2019 Not available
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WAIST HIP RATIO (ADJUSTED BY BMI) rs975385 C miss 0.011 Pulit et al. 2019 Not available
WAIST HIP RATIO (ADJUSTED BY BMI) rs9909443 C miss 0.014 Pulit et al. 2019 Not available
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Supplementary table 3. ACR results of meta analysis of multivariate Mendelian randomization results for lipids adjusted by other lipids' betas in UK Biobank and CKDGen 
and in the two studies individually. 95% confidence intervals in brackets.
  Meta analysis
Trait Beta IVW P IVW Beta Egger P Egger Beta WM P WM Beta PWM P PWM
TRIGLYCERIDES adjusted by 
LDL CHOLESTEROL and HDL 
CHOLESTEROL 0.094 (0.073, 0.115) < 1 x E-15 0.112 (0.081, 0.144) 1.3E-02 0.052 (0.033, 0.071) 1.1E-07 0.048 (0.029, 0.068) 1.1E-06
HDL CHOLESTEROL adjusted 
by TRIGLYCERIDES and LDL 
CHOLESTEROL 0.011 (-0.005, 0.028) 1.7E-01 0.029 (0.006, 0.052) 1.3E-02 0.008 (-0.007, 0.024) 3.0E-01 -0.008 (-0.028, 0.012) 4.3E-01
LDL CHOLESTEROL adjusted 
by HDL CHOLESTEROL and 
TRIGLYCERIDES
0.018 (0.001, 0.035) 3.4E-02 0.014 (-0.012, 0.040) 3.0E-01 0.029 (0.014, 0.045) 1.8E-04 0.032 (0.016, 0.048) 9.6E-05
UK Biobank 
Trait Beta IVW P IVW Beta Egger P Egger Beta WM P WM Beta PWM P PWM
TRIGLYCERIDES adjusted by 
LDL CHOLESTEROL and HDL 
CHOLESTEROL 0.069 (0.040, 0.098) 2.1E-05 0.092 (0.049, 0.134) 1.1E-04 0.048 (0.027, 0.070) 1.0E-05 0.044 (0.022, 0.066) 8.5E-05
HDL CHOLESTEROL adjusted 
by TRIGLYCERIDES and LDL 
CHOLESTEROL 0.003 (-0.018, 0.024) 7.6E-01 0.017 (-0.014, 0.048) 2.8E-01 0.002 (-0.016, 0.019) 8.6E-01 -0.035 (-0.060, -0.009) 8.6E-03
LDL CHOLESTEROL adjusted 
by HDL CHOLESTEROL and 
TRIGLYCERIDES
0.015 (-0.004, 0.034) 1.2E-01 0.026 (-0.004, 0.055) 9.1E-02 0.032 (0.016, 0.048) 1.1E-04 0.033 (0.016, 0.050) 1.5E-04
CKDGen 
Trait Beta IVW P IVW Beta Egger P Egger Beta WM P WM Beta PWM 0.07
TRIGLYCERIDES adjusted by 
LDL CHOLESTEROL and HDL 
CHOLESTEROL
0.123 (0.092, 0.154) 4.6E-10 0.136 (0.091, 0.181) 3.6E-07 0.064 (0.023, 0.106) 2.5E-03 0.064 (0.022, 0.106) 2.8E-03
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HDL CHOLESTEROL adjusted 
by TRIGLYCERIDES and LDL 
CHOLESTEROL 0.024 (-0.002, 0.049) 7.8E-02 0.044 (0.010, 0.079) 1.4E-02 0.031 (-0.002, 0.063) 6.4E-02 0.031 (0.000, 0.062) 5.4E-02
LDL CHOLESTEROL adjusted 
by HDL CHOLESTEROL and 
TRIGLYCERIDES
0.028 (-0.007, 0.064) 1.2E-01 -0.031 (-0.012, 0.040) 3.0E-01 0.029 (-0.047, 0.056) 8.6E-01 0.026 (-0.027, 0.080) 3.4E-01
IVW = inverse variance weighted instrumental variable analysis, WM = weighted median analysis, PWM = penalised weighted median analysis.
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Supplementary Table 4. UK Biobank and CKDGen grs and two sample Mendelian randomization results between investigated traits and ACR.
UK Biobank
Trait Beta grs SE grs P grs Beta IVW SE IVW P IVW Beta Egger
SE 
Egger P Egger
Egger int 
p
Beta 
WM SE WM P WM
Beta 
PWM SE PWM P PWM
Diastolic BP 0.0839 0.0105 1.4E-15 0.0075 0.0018 7.6E-05 0.0011 0.0051 8.3E-01 1.83E-01 0.0080 0.0016 1.0E-06 0.0057 0.0021 5.9E-03
Systolic BP 0.0835 0.0115 4.7E-13 0.0035 0.0012 5.1E-03 0.0035 0.0038 3.6E-01 9.98E-01 0.0046 0.0010 6.2E-06 0.0037 0.0014 6.5E-03
HDL cholesterol -0.0198 0.0065 2.4E-03 -0.0133 0.0122 2.8E-01 -0.0041 0.0179 8.2E-01 4.84E-01 0.0087 0.0091 3.4E-01 -0.0058 0.0171 7.4E-01
LDL cholesterol 0.0204 0.0059 4.9E-04 0.0271 0.0157 1.3E-02 0.0361 0.0160 2.8E-02 4.53E-01 0.0334 0.0088 1.4E-04 0.0270 0.0099 6.5E-03
Triglycerides 0.0568 0.0070 3.6E-16 0.0548 0.0149 6.1E-04 0.0581 0.0220 1.1E-02 8.37E-01 0.0460 0.0116 7.0E-05 0.0460 0.0188 1.5E-02
BMI 0.0260 0.0126 3.9E-02 0.0068 0.0149 6.5E-01 0.0916 0.0313 4.2E-03 2.76E-03 0.0093 0.0161 7.8E-01 0.0286 0.0194 1.4E-01
% Body fat -0.0758 0.0440 8.5E-02 -0.0661 0.0652 7.2E-01 0.2180 0.1532 9.0E-01 7.31E-02 -0.1170 0.0477 5.7E-01 -0.0753 0.0744 7.7E-01
Waist hip ratio
 (adjusted by 
BMI)
0.0391 0.0077 3.7E-07 0.0357 0.0106 8.8E-04 0.0936 0.0255 2.7E-04 1.28E-02 0.0503 0.0122 3.6E-05 0.0321 0.0127 1.1E-02
Fasting glucose -0.0005 0.0004 1.7E-01 -0.0038 0.0370 9.2E-01 -0.0074 0.0727 9.2E-01 9.54E-01 -0.0143 0.0253 5.7E-01 -0.0125 0.0274 6.5E-01
Fasting insulin 0.0000 0.0006 9.9E-01 -0.0810 0.1364 5.7E-01 -0.8563 0.7542 2.9E-01 3.21E-01 -0.0415 0.0725 5.7E-01 -0.0394 0.0844 6.4E-01
T2D 0.0010 0.0003 6.4E-04 0.0176 0.0041 5.53£-05 0.0232 0.0082 6.5E-03 4.4E-01 0.0233 0.0051 5.2E-06 0.0260 0.0063
3.28E-
05
Grs= genetic risk score, IVW = inverse variance weighted instrumental variable analysis, WM = weighted median analysis, PWM = penalised weighted median analysis, Egger int p = Egger p for intercept.
CKDGen
Trait Beta grs SE grs P grs Beta IVW SE IVW P IVW
Beta 
Egger
SE 
Egger P Egger
Egger 
int p
Beta 
WM SE WM P WM
Beta 
PWM
SE 
PWM P PWM
Diastolic BP Not available Not available Not available 0.0136 0.0029 1.3E-05 -0.0062 0.0082 4.5E-01 1.1E-02 0.0143 0.0035 4.0E-05 0.0143 0.0035 5.6E-05
Systolic BP Not available Not available Not available 0.0104 0.0019 3.7E-07 -0.0043 0.0055 4.3E-01 5.5E-03 0.0097 0.0022 1.1E-05 0.0098 0.0021 4.4E-06
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HDL cholesterol Not available Not available Not available -0.0098 0.0131 4.6E-01 0.0269 0.0175 1.3E-01 3.0E-03 0.0307 0.0161 5.7E-02 0.0307 0.0161 5.7E-02
LDL cholesterol Not available Not available Beta grs SE grs P grs 2.4E-01 -0.0262 0.0292 3.7E-01 4.3E-02 0.0029 0.0265 9.1E-01 0.0253 0.0259 3.3E-01
Triglycerides Not available Not available Not available 0.0697 0.0159 6.0E-05 0.0713 0.0231 3.4E-03 9.3E-01 0.0641 0.0212 2.5E-03 0.0641 0.0214 2.7E-03
BMI Not available Not available Not available 0.0885 0.0292 3.4E-03 0.0662 0.0717 3.6E-01 3.9E-03 0.0559 0.0434 2.0E-01 0.0562 0.0434 2.0E-01
% Body fat Not available Not available Not available -0.2947 0.0804 2.9E-03 -0.2399 0.2355 3.3E-01 8.0E-01 -0.3053 0.1197 1.1E-02 -0.3053 0.1147 7.8E-03
Waist hip ratio 
(adjusted by BMI) Not available Not available Not available 0.0651 0.0271 1.7E-02 0.1478 0.0805 6.8E-02 2.8E-01 0.0435 0.0398 2.7E-01 0.0305 0.0407 4.5E-01
Fasting glucose Not available Not available Not available -0.0337 0.0499 5.1E-01 -0.0921 0.0940 3.4E-01 4.7E-01 -0.0321 0.0560 5.7E-01 -0.0321 0.0551 5.6E-01
Fasting insulin Not available Not available Not available 0.0561 0.1483 7.1E-01 -1.8712 0.8257 4.3E-02 2.9E-02 -0.0150 0.1282 9.1E-01 -0.0150 0.1287 9.1E-01
T2D Not available Not available Not available -0.0133 0.0100 1.9E-01 0.0022 0.0216 9.2E-01 4.2E-01 -0.0009 0.0164 9.5-01 -0.0009 0.0164 9.5E-01
Grs= genetic risk score, IVW = inverse variance weighted instrumental variable analysis, WM = weighted median analysis, PWM = penalised weighted median analysis, Egger int p = Egger p for intercept.
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No evidence of heterogeneity was noted between the MR estimates for the two diferent studies for HDL 
(p = 0.844, I-square 0.0%), LDL (p = 0.788, I-square 0.0%) and triglycerides (p = 0.494, I-squared 0.0%).
Standard deviation diferences in ACR per standard deviation diferences in geneticaly instrumented
lipids measures.
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